Các yếu tố tiên lượng và các thang điểm đánh giá nguy cơ trong nhồi máu cơ tim cấp

chuyengiataichinhcom 23 views 74 slides Oct 31, 2024
Slide 1
Slide 1 of 74
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67
Slide 68
68
Slide 69
69
Slide 70
70
Slide 71
71
Slide 72
72
Slide 73
73
Slide 74
74

About This Presentation

Trong những thập niên gần đây bệnh tim mạch đang là một trong những vấn nạn của sức khỏe toàn cầu, là nguyên nhân hàng đầu gây tử vong ở các nưởc đã phảt triển và đang phát triển. Hàng năm có 17,3 triệu người chết vì các bệnh l...


Slide Content

poo on ro
BO GIAO DUC VA DAO TAO

DAI HOC HUE
TRUONG DAI HOC Y DUQC

GIAO TH] THOA

Chuyén dé 1
CAC YEU TO TIEN LUQNG VA
CAC THANG DIEM DANH GIA NGUY CO
TRONG NHOI MAU CO TIM CAP

Huróng din khoa hoe:
PGS TS NGUYEN LAN HIEU
GS TS HUYNH VAN MINH

HUE - 2014

AI rr ADE à

ascii om

MUC LUC

CHO VIÉT TAT

DANH MUC CAC BANG

DANH MUC CAC SO DO, BIEU BO

L DAT VAN DÉ

IL. NOLDUNG
2.1. CAC YEU TO TIEN LUGNG
2.1.1. Yu té nguy co
2.1.2. Ving nhdi máu trén dien tam 43
2.1.3. D6 röng cúa ving nhöi méu
2.1.4, CK, CK MB
2

‘Troponin LT
2.1.6. NT pro BNP

2.1.7. H-FABP

2.1.8. Dudng huyét

2.1.9. Chite näng thin

2.1.10, $6 hrong bach chu mäu

2.1.11. Protein phän img C dó nhay cao (hs-CRP)
2.1.12. Thiéu méu

2.1.13. Ré loan chive ning that tri

2.1.14. Thiéu méu co tim tai phat

2.1.15. Ri loan mhip tim

2.2. CAC THANG DIEM DÄNH GIA NGUY CO
‘Thang diém TIMI

2.2.2. Chi só nguy co TIMI

2.2.3. Thang diem nguy co MAYO.

ascii om

Trang

10
13
15
17
18
20

2
26
28
30
32
35
36

2.2.4. Thang diem nguy co GRACE

2.2.5. Chi só nguy co Zwolle

Thang diém nguy co CADILLAC
2.2.7. Thang diém nguy co PAMI
2

So sinh các thang diem dänh gia nguy co
Ml KET LUAN
‘TAI LIEU THAM KHAO

Maps éhuyengiaticin com

37
38
40
a
42
44

CHU VIET TAT

CK: Creatine Kinase
(CK-MB: Creatine Kinase - Myocardial Band
BMV: Bénh mach vanh

BMV: Dong mach vanh

DID: Dái thio duöng

DTN: Dau thit ngue

DTNKÓD: Dau thit nguc khong ón dinh

EF: Ejection Fraction (phán suát tng méu)

GRACE: Global Registry of Acute Coronary Events (bién có döng mach vanh
cp theo só bé toán chu)

HATT: Huyét dp tam thu

HATTr: Huyét äp tám truvng

HCVC: Hôi chimg vanh cáp

H-FABP: Heart type Fatty Acid Binding Protein

hs-CRP: high-sensitivity C-reactive protein (protein phan img C d6 nhay cao)
NMCT: Nhôi mau co tim

NMCTSTCL: Nhói mau co tim ST chönh lén

NMCTKSTCL: Nhöi máu co tim khöng ST chénh len

NSTEME: non ST segment elevation myocardial infarction ( nhéi mau co tim
khong ST chenh len)

NT pro BNP: N-terminal fragment pro B-type natriuretic peptid (Peptide thai
natri loi nigu phän doan N cuói cing)

NYHA: New York Heart Association (Higp hoi Tim mach New York)

PAME Primary Angioplasty in Myocardial Infarction trials (can thigp dông

mach vanh nguyén phät 6 nhôi mau co tim cáp)

ascii om

STEML: ST segment elevation myocardial infarction (nhöi máu co tim khóng
ST chénh len)

THA: Tang huyét áp

TMCBCT: Thiéu mâu cue bó co tim

TIME: Thrombosis In Myocat
XVDM: Xo vita dóng mach
YTNC: Yéu tó nguy co

al Infarction (Huyétkh6i wong nhöi mau co tm)

ascii om

DANH MUC CAC BANG

Bang 1. Ty 18 tir vong 6 tuán dâu sau NMCT theo só long các yéu
té nguy co

Bang 2. Möt só cdc nghién cúu nông dó Troponin

à tir vong trong
30 ngáy dau

Bing 3. Phin dó Killip va tr vong

Bang 4. Ty 18 tir vong 30 ngäy dura trén phän d6 KILLIP

Bang 5. Rôi loan nhip that va ty 16 ti vong

Bing 6. Thang dim TIMI déi vói HCMV cáp khóng có ST chénh lén

Bang 7. Thang diem TIMI déi voi HCMV cép có ST chénh len

Bang 8. Nguy co tir vong theo chi só nguy co TIMI

Bang 9. Thang diem MAYO

Bang 10. Các yéu tó thang diém nguy co GRACE

Bing 11. Chi sé nguy co Zwolle

Bang 12. Thang diém nguy co CADILLAC

Bing 13. Thang diém PAMI

Bang 14, So sánh các thang diem dánh gia nguy co

ascii om

Trang

23
24
30
32
33
35
36
38
39
40
a

DANH MUC CAC HINH, BIEU DO

Trang
Hinh 1. Möi in quan các yéu tó nguy co va tir vong 3
Hinh 2. Rói loan chite náng that träi sau nhôi mau co tim 2
Biêu dé 1. Lién quan git ving nhdi méu va tir vong 5
Bidu dé 2. Méi lién hé gitta nông dó CK huyét thanh va tir vong
hoje NMCT tál phät trong 6 thing 7

bu dó 3. Nong dó CK-MB huyét thanh va ti vong 8
Bidu dé 4. Ty 1é tir vong 30 ngay theo nóng 46 Troponin T 10
Biéu dé 5. Ty Ié tir vong theo nóng d BNP u

Bigu dó 6. Ty 6 tirvong trong 6 thing du theo nóng dá NT-proBNP 12

45 7. TY 16 tirvong trong näm däu theo nóng 46 NT- proBNP 12

Bidu dó 8. Xác suit sng cón theo diêm cát nóng 46 NT-proBNP 13
45 9. Nong dó H- FABP va ty 18 cie bién có sau NMCT 14

45 10. Nóng dó Tnl, H- FABP va ty lé tür vong trong nim däu 15

éu dé 11. Nóng dó dwöng huyét va bién có tim mach 16

u dó 12. Duröng huyét lie nhäp vién va 13 16 tr vong 7
Bidu dó 13. Nguy co tir vong vá dó loc cáu than 18
Lién quan gitta bach cáu va tirvong trong 30 ngáy dâu 19

‘TY Ig tirvong theo diem GRACE va thiéu méu 21

Chi só LI va ty 16 tir vong 2

Phan suát tng máu that trái va tú vong 24

Biéu dó 18. Tinh trang sóc tim va tú vong 25

Biéu dó 19. Dau thit ngue sau nhdi mâu vá thay dói doan ST trong
tién doán NMCT tai phat 2

ascii com

Biéu dé 20. Thiéu mau co tim tai phat vá ty 16 sóng con 2
45 21. Rung mhi vá ty 13 sóng cón 28

Biéu dá 22. Diém nguy co TIMI déi véi Hôi chimg vanh cáp khóng ST 33
| ehönh lin
Bidu dd 23. Ty 16 tir vong hoëc nhöi máu co tim trong 30 ngay vá 1 nám &

hói chimg vanh cáp khong ST chénh lén theo diem TIMI 34

Biéu dó 24. Ty Ié tit vong theo diem TIMI 6 Höi chimg vanh cáp ST

chénh len

48 25. Diém nguy co MAYO va ty Ié tir vong
Biéu dé 26. Ty 16 tir vong theo chi só nguy co Zwolle 40
Biéu dó 27. Ty lé tir vong theo thang diem CADILLAC 41
Biéu dó 28. Thang diém nguy co PAMI va ty 16 tir vong 6 bénh nhän

STEMI 2

ascii om

I. DAT VAN DE

‘Trong nhiing thép nién gán däy bénh tim mach dang la mót trong nhiing
van nan cúa sire khóe toán cau, lá nguyén nhán hang dau gay tir vong ö các

nude dä phät tién vá dang phä win. Hang näm có 173 tigu nguvi ché vi

‘cde bénh Iy tim mach, chiém 30% tóng ty 16 tir vong trén toan thé gigi. Trong

46 hon 80% cäc tnröng hop tir vong & các muse có thu nhäp tháp va trung

binh. Nam 2015, WHO use tinh ty 16 tir vong may vao khoäng 20 triéu nguöi.
én nim 2030, các nha nghién ciru du bio con só nay hon 23,6 triêu va bénh
tim mach sé la nguyén nhan chinh gay tir vong ren toán thé giói [40], [149].
Ó Chau Au, theo cóng bé méi nhát näm 2013, tim mach la nguyén nhán gay

47% truóng hop tir vong & Chau Luc nay [90]

Trong dé, nhöi máu co tim (NMCT) cáp la mót trong nhüng nguyén

nha gay tir vong hing däu. NMCT xäy ra khi tác nghén dôt ngôt mach mäu
nuôi duöng tim. Co ché chü yéu la do sw khöng ôn dinh va nút ra cúa mang
xo vila, trén co só dé huyét khói hinh thanh gáy láp toan bö löng mach.
‘Theo théng ké cúa WHO, häng näm trén thé gidi có 7.3 trigu nguói chét do
bénh BMV [149]. Dich
Mf, theo bâo cäo nim 2014 cúa Höi Tim Mach Hoa Ky, tÿ 18 mói n
NMCT hing nam là 515.000 tnröng hop vá có 205.000 truéng hop NMCT

190 NMCT khác nhau timg nude va khu ve. Tai

ic

ti phät. Nhüng truóng hop NMCT län dau, có dó tudi rung binh & nam la
64,9 va 72,3 vói nit [7]. Tai Chau Au, cir möi 6 nam giói va mdi 7 nit giói
Jai có 1 ngudi bi tr vong do NMCT [5]. Tai Anh, näm 2010, ty 16 tir vong
do NMCT trén 100.000 dn la 39,2% & nam va 17,79% 6 nit [104]. Ó Trung
Quöc, ty 18 chét do bénh mach vanh là 100/100.000 & nam giói va
69/100.000 6 nú. Ó Chau Phi Den, tÿ 18 bénh tim thidu más cue bó chiém
25% ti 18 chét toan b6 [154].

1

ascii om

Tai Viêt Nam, tuy cha có 56 ligu théng ké cu thé nhumg só nguöi mi

bénh tim mach dic biót la só bénh nhân NMCT ngay cing gia ting nhanh

chông [2]. Néu nhur nhimg nim 50, NMCT IA

bönh rät hiém gap th

n may
hit nhurngäy náo cúng gap nhing bénh niin nhöi má co tim cáp nhäp vi,

fe chau lue, chi phi dièu tri

Ó tit ei các quée fe bénh If tim mach
tr6 thinh gänh ning kinh té Nim 2010, tai MY ude tinh chi phi cho didu tri
bénh tim mach la 272,5 tÿ 46 la, trong dó bénh DMV là 35,7 tÿ. Dén nám
2030, chi phi nay ting län luot IA 818,1 va 106,4 ty dó la. Ó Chau Au, chi phi
hang näm dänh cho các bénh Iy tim mach la 196 1ÿ Euro. Nam 2010, tai Pháp,
Régime Général, mót bó phán cúa bio hiém xä hói Php phäi chi 15,516 ty

euro cho các bénh Iy tim mach [81], [91], [153]

Vige chin doán va diéu tri som dóng vai tr quyét dinh trong vide ci

séng bénh nhän nhöi miu co tim. Các bión phép can hiép kip thoi có thé han

phuc mót só ving méi t

i da ving co tim bi chét, thuong, giám

thigu duge 1} 18 tir vong va nhüng bién có tim mach, Higu quá digu tri sé tôt
ahi
luong bénh NMCT cüng dóng vai tró cue ky quan trong; vi day lá yéu 16

néu bénh nhán duoc xir tri trong vöng 01 giè dâu. Ben canh dé, viéc tin

quyét dinh huóng xir tri, theo döi bénh, vá cúng là co só dé giái thich cho
gui nha bénh mhán.

Chiinh vi vig, trong chuyén 42 rity, chüng (61 38 &i niu vio tim ida vé
de yéu 16 tién lucomg trong nhöi mau co tim câp dé viéc diéu tri, cham sóc,
‘theo döi va dur hi tôt hom,

2

ascii om

11. NOI DUNG

2.1. CAC YEU TO TIEN LUONG
2.1.1. Yén tó nguy co

Trong 30 ngäy dau, các yéu tó tien lugng tir vong bao göm: tuói,
trang suy tim sung huyét, huyét áp, nhip tim lúc nhäp vien, vi tri ving NMCT,
tión sit NMCT, nit giói, hit thude lá; tión sir bénh tim mach, THA, DTD.
(21), (31), (82), (1151

Dura trén thir nghigm GUSTO- I, Lee va cóng su mó tá möi lién quan
gif các yéu 16 nguy co nay vo

à 16 tir vong theo hinh tháp (Hin 1) [39].

Tease
gah
tim mach (04%)

‘Ta si bát cu adi DMV 08%)

Tanée (08%) Cin njng( 0,8%)

Cha ao) ID (1%)

Tien st NMCT(62%)

MATT pe 24%)

Hinh 1. Méi gitta các lien quan các yéu tó nguy co véi ti tie vong [39].

3

Maps éhuyengiaticin com

Trong nghién cu cia David Hills va cóng sir cho thy ti 16 tit vong ting
dan theo só long ede yéu 16 nguy co (Bang 1) {70}

BANG 1701

y e te vong 6 tudn däu sau NMCT theo só trong các ydu 16 nguy co

o 15)
1 23
2 70
3 13.0

>=4 172

‘Tudi a yéu 46 nguy co chinh lim gia ting ty 16 tú vong 6 béah nl
NMCT, Tuói cao la yéu 16
trong nhiéu nghién cru. Trong thir nghiém GUSTO-1 tir vong sau 30 ngay &
nhóm > 75 tuói la 20,5%, & nhóm < 45 tuái la 1,1% [83]. Trong thir nghiém
“TIMI UI ir vong sau 42 ngày 6 nhôm > 70 tuêi la 11,2% (701.

én Itong quan trong va döc lap duge chúng minh

2.1.2. Ving nhôi mau trén dién tâm dd
Vi tr nhdi mâu la yéu 16 tión long quan trong & bénh nhän NMCT. Vi
tri vüng NMCT ving trade có nguy co tir vong gáp hai lin NMCT ving dui
Thür nghiem GUSTO-I, ty 18 tir vong trong 30 ngay la 9.9% véi nhöi máu
Vüng trude va 5,0% vói ving dud [82].
Nghién ciru 6 4.990 bénh nhán NMCT cáp duyo di

Ari bing can thigp
DMV qua da, trong dó NMCT ving truóc chiám 1ÿ 18 dén 49,8%. NMCT
vüng truóc lien quan vói ting nóng dó CK huyét thanh, giäm phan suát tng
mâu that wi, Trong näm däu, ty 18 tir vong à nhom NMCT ving trude la
8,8% so vi 58% & nhém nhöi méu Không phai ving trude. Ty 13 chua higu
chinh cúa hai nhôm nay IA 1,56 % (Biéu dó 1)[105).

4

Maps éhuyengiaticin com

‘Tir vong( %)
10-

y 12
Bidu 08 1. Liön quan giga ving nhô mau va ti vong [105].

‘Ty lé tir vong trong 30 ngäy & nhôm có sóng Q hoai ti A 7% so véi
nhôm khöng có sóng Q la 2% [12].

‘Thir nghiém ASSENT-3 trén 4.565 bénh nhän nhöi mäu co tim ST chönh
en nhäm dänh gid sw giám doan ST sau 180 phüt dièu tri tiEu soi huyét. Sur
gidm doan ST > 50% sé giám tán suat tir vong 30 ngäy va 1 näm so vói nhém
khong cái thign doan ST (3,7% so vöi 7,3% va 6,1% so vöi 10%, p< 0,001)
[135]. Ngoai ra, su giäm doan ST có lién quan v

nông dó CK huyét thanh vá thang diem QRS cha Selvester [751
2.1.3. Dé róng cüa ving nhöi mau

Tién luong xáu neu d6 rong vüng nhöi máu (khöi luong ving co tim bi
hoai ti) cAng lón, thé hién trén dien tam dé la mite dó chénh hay só chuyén
dao chénh cia ST cing cao, kèm sóng QS cúa hoai ti xuyén thänh thi 19 16 ir

vong cäng ting [115]. Trén ECG doan ST chénh xuöng 0,0Smm có ti 1é

vong hay nhôi mau co tim täi phat trong 30 ngay däu la 10,5% [121].

5

ascii com

DO röng thuong tn cüng nhu mire dó rói loan ván dóng thanh tim the

dáy xuát hién suy tim. Nhümg nghién ciru true day, phán suát tóng máu va

thé tich cudi tam thu that tri la yéu 16 dur báo quan trong ty 16 tir vong [100],

11231. Tuy nhién, nhümg nghién edu gin diy cho tháy, dien ich nhô mau có

én quan truc tiép dén tái cáu trúc that ti va la yéu 16 quan trong trong tiên
lung sau nhöi máu co tim cp, thám chf trén nhüng truóng hop có chire nang,
‘am thu that tr nim trong giói han binh thuróng [151].

U hrong dé róng thuong tén bing nhiéu phuong pháp khäc nhau. Ly
tuóng là cc phuong pháp khóng xám nháp, có thé sir dung som dé dánh gia
4 róng hoai tir cüng mite lan róng cúa nó. Nhümg phuong phäp thuóng sir
dung trén lm sing : (1) Binh Iuong các chat chi diém sinh hoc, (2) Dién tim,

(3) Sicu am tim,

2.1.4. CK, CK MB
Tir nhimg nim 1970, trong hai nhóm nghién cin déc láp Witteveen et al
va Sobel et al di dura vide do luóng các chit chi diem sinh hoc va dién tích

shi mu va möi En quan vei in long sau NMCT [126], 11271. (144)

‘Va nhiéu nghién ciru sau nay chimg tó méi tuong quan thuán gitta CK,
CK-MB vói sy lan róng cia ión thong va gia ting 6 18 tir vong. Hay ndi
cách khác, có thé ding các men tim nay dé dänh giä dien tích ving t6n thong,
vá qua dur ra tién lung cho cäc tnröng hop NMCT.

Trong thit nghiém GUSTO-IIb & 12.142 bénh nhán NMCT cáp, nöng dó
CK (hoïc CK-MB) có tuong quan thuán vói ti vong va NMCT tai phat trong
6 thing [120] (Biéu dé 2). Giä tri cia nóng dó CK huyét thanh cüng có ÿ nghia

tién lugng & bénh nhân nhöi máu co tim ST chénh có can thigp dóng mach

vanh qua da nguyén phat [67].

6

ascii om

"Ti vong hay NMCT trong 6 thing

0,05) — NMCT ST không chénb ln
=== NMCT ST chönh lén
o
5 10 15 20

n hé giita nóng d6 CK huyét than vá tie vong hode
NMCT täi phat trong 6 thing [120].

Nghién cúu 4.670 bénh nhán nhói mau co tim cáp ST chénh len duoe
digu tri can thigp dóng mach vanh, nóng dó CK va CK-MB la yéu 16 tin
luong dóc láp cúa rói loan chúc nang that trai vá tí vong 1 nim, vói ty só
guy co lá 2,28 vá 1,91 [106]

CK-MB

hät chi diêm ci

su hoai tir té bao co tim vá có gid tri

luong tir vong. Két quä nghién ciu trén 4 thi nghiém ln GUSTO Ib,
PARAGON A-B va PURSUIT trén 25.960 bénh nhän, duge phän thanh 4
nhôm: (1) CK binh thudng + CK-MB binh thuróng, (2) CK binh thuóng + CK-
MB ting, (3) CK ting + CK- MB binh thuróng vá (4) CK ting + CM-MB ting,
thi nhôm thir 2 66 bién có nhôi mäu co tim vá tir vong trong 180 ngáy cao
nhät, chiém 20,8%, trong khi cée nhôm cón lai Jän luot IA 14,9%, 14,5% va
18,2% (Biéu dé 3). Va bat Ki nóng do CK, ting nöng 46 CK-MB lién quan tir
25% dén 49% su gia ting các nguy co bién có [54].

7

ascii om

] CK binh thuög/ CK- MB ting
i ck va CK: MB UNE
5 E
3 in hOB
a ck va OK: MB DU
E ‘MB binh Ihuöng
3 r
É
30 o E 120 150 Fo

Neay
Biêu dó 3. Néng dó CK-MB huyét thanh vá tie vong [54].

2.1.5. Troponin 1,T
Troponin I (cTnl) va T (cTnT) la 1a chát chi diém e

hoai tir eta té bao

co tim vói dé nhay vá dic higu cao. Tir khi phat hién ra eTn'T dä dat ra van dé

1 có mdi quan hé mio that sw gita dien

ch nhöi mé

va nông dé

n hänh.

ia nó hay

khong ? Dé tra loi cáu hói nay, nl

u nghién cinı duge

Nam 1991, Hugo va cóng su dä mó tá môi lien hé git troponin TnT
vai dién tich tón thuong. Sau dó có rät nhién cöng tinh nghién cúu vé mdi
lién quan nay vá dä có mót két luán chung la eTnT có mdi quan hé chat ché
vói dien tich nhöi mâu, 1ÿ 18 tir vong sau NMCT ting din theo nóng dó
‘Troponin mu, dic biét 6 nhiing trröng hop NMCTSTCL [76] (Bäng 2) [109],
(110), 1112)

8

ascii om

1109), (110), (112)

: : ‘ E = = vat le = rt fäu

Filippo [N: 18982 + STEMI
Otani et | Phan tich göp tir 21 nghièn ein ix | (+) tinh 179
al (2000) | nim 1990-2000 . 9
i duge chin doán höi chimg Dia)
vanh cáp + NSTEMI
‘Tie vong 30 ngay (+) tin 59
© üinh 13
E.Magnus | GUSTO-IIL
‘Ohman et | N: 12666 (+) tinh 157
al (1999) | Dau ngue tir 30ph- 6h
STEMI hay Bloc can tri Ouh 62
Tir vong 30 ngày
E.Magnus | GUSTO-IIa
‘Ohman et | N= 855 > 0.1 ng/ml 118
al (1996) | Dau ngue trong 12h
ST chénh len hose xuóng itnhat |=<0.1ng/ml | 3.9

(0.05 mV, Bloc canh trái hay T dio
nguoc ft nhây 0.1 mV
‘Tit vong 30 ngay

Trong thir nghiém GUSTO-III Ö 12.666 bénh nhân NMCTSTCL: 8,9%
bénh nhan có Troponin lúc nhäp vién ting (> 0,2 g/l) có tÿ 16 tir vong cao
trong 30 ngày so véi Troponin am tinh (15,7% so vói 6,2%). Troponin T la
möt yéu tó tión Irong tir vong dôc lap trong vong 30 ngay [110].

Nghiën ciru GUSTO-Ila ching minh tim quan trong cüa Troponin ting
sóm vá nhe 6 nhiing bénh nhän HCVC vói dau thát ngue va bién dói diên tai
4, Trong 801 bénh nhän NMCT gdm 289 bénh nhán có ting nóng dó TaT
(00,1 gf). Ty 18 tú vong trong 30 ngáy ting cao có ÿ nghia so véi nóng do

9

ps Icngiaachinh com

‘THT tháp (11,8% so vói 3,9%, p < 0,001). Dac biét, có tuong quan tuyén tinh
gitta nông dó TnT vói tir vong. Nöng 46 TnT có giá tri tión luong cao hon so
vi thay döi diên tim dó va men CK-MB (Bidu dé 4) [109].

0,00. Nang 49 Troponin TC mg mt)

Bidu dé 4. Tÿ 18 tie vong 30 ngay theo nông dö Troponin T [109].
‘Trong phan tích góp 21 nghién cu trén co só dir ligu Medline tir 1990-
2000 gdm 18,982 bénh nhân HCVC cho théy nöng dö Troponin T.I có lien
quan vói ting nguy co tir vong tim mach hoñe NMCT tái phat trong 30 ngay
(4,4% so vói 8%, OR= 3,44). Ning dó Troponin T la yéu 16 tién Iuong 30 ngdy
va dur há läu dai (5 thang dén 3 näm) 6 nhüng bénh nhân NMCT ST chénh len
(OR 2,86 va 3,11) hoc ST khöng chénh len (OR 4,19 va 2,79) [112].

2.1.6. BNP (B-type natriuretic peptid) va NT proBNP(N-terminal fragment
pro B-type natriuretic peptid):

BNP la mot peptide loi
1371. Gen bién 16 BNP nim trén nhiëm sic 1

sin phim dáu tién la Pre-proBNP. Peptid nay duye phän tách nhó các enzym

su tim mach, tap trung chü yéu & täm that [34],

1. Sau khi gi

thanh tién hormon (pro-BNP), Sau d6 pro-BNP duge tách ra thanh BNP va NT-
proBNP [881.140]. NT-proBNP duce tiét 70% tir co thât, möt lugng nhö 6 co

nhi, & nâo, ph

than, dông mach cha va tuyén thugng than nhumg v

nóng 46

thip hon 6 mbr. Sr phóng thich cúa NT-proBNP duge diéu tiét boi áp hye va thé

10

ascii om

ch that tri, Tinh trang gia ting sire cing thinh co tim la yéu tó

ich thich
manh mé sw phóng thich BNP va NT- proBNP [88], [140]. Ó bénh nhân
NMCT, nóng dó BNP va NT-proBNP ting nhanh chóng sau dh däu vá dat dinh
16i da váo thoi diem 20-30 gio [73],

Di có nhidu nghién ciru dá chimg minh mdi quan hé gira nóng 46 cüa
BNP va NT-proBNP véi dien tich nhöi mau, röi loan chire näng that träi va ty
16 tr vong sau nhôi máu co tim [16], [68], (117), 11321.

Trong nghién cóu trén 2525 bénh nhän HCVC, gm 825 NMCT có ST
chénh lén va 565 NMCT không ST chénh lén, cho thay nóng dó BNP ting cao
ó nhüng bénh nhân có d6 Killip II, III hay IV, va 6 nhüng bénh nhân có sir
bién dói trén dien tim, có ting ndng d CK-MB. Ty lé tir vong ting thuân theo
nöng dó BNP, däc biét ó nhôm NMCTKSTCL (Bidu dé 5) [72].

16 5,0- 43,6 pg/mi
TAO
po CRE
2
Ea
o

‘STEMI
Bidu dé 5. 7) lé ti vong theo nóng dó BNP (72).

Trong thir nghiém TACTICS-TIMI 18 trén 1.676 bénh nhân nhöi mäu co
tim khóng ST chénh có ting BNP trong vóng 2 nim (1997-1999) cho tháy
nhing truóng hop có nóng dé BNP > 80pg/mL. có ty lé tir vong trong 17 ngäy
du vá 6 thang dau lán lugt IA 2,5% , 8,8% so vói nhôm không ting BNP là
0,1% va 1,8% (Bién dö 6). Va BNP
yéu tó tión long Khác [44]

yéu 16 tién lung döc läp so vói các

u

ascii com

BNP > 80 pe/m!
= = = BNP < 80 pg/ml

£
3 6 thing
4 8,4% so véi 1,8%]
BS p= 0,0001
of Neäy
$ 30 160 0 150
Bidu db 6.75:

tie vong trong 6 thang däu theo néng 46 NT: proBNP (44).

Gi tri tin Iuong cúa NT proBNP cüng gin mhur tuong duong véi BNP.
Nghién cin GUSTO-IV trén 6809 bénh nhän HCVCKSTCL cho tháy nguy co
mic bién có NMCT cáp trong vóng 30 ngáy có lién quan dén tinh trang ting
nóng d6 NT-proBNP huyét thanh . Trong trong 30 ngay, t$ 1é bién có NMCT
theo các nhém NT-proBNP (< 237, 238-668, 669-1869 va > 1869 ng/L) län
Auot A 2,7%, 5.4%, 5,7% va 7,5% , p < 0,001 (Bidu dé 7) 129)

er

HD [2 380

y 16 ti vong trong nám däu theo nóng do NT- proBNP (129).

2

ascii com

Möt nghién ci khéc trén 755 bénh nhán dau thát ngve nhép vién ti don
vi tim mach can thigp nghi ngú HCVC khóng có ST chénh lén cho tháy nhém
fin có nöng dó NT-proBNP >1654 ng/L có nguy co tit vong hon 26 län

bénh nl
so vói mhóm NT-proBNP <112 ng/L (74).

‘Trong nghién citu cüa Tran Viát An trén 127 bénh nhän HCVC cho tháy
nhôm bénh nhán có nóng d6 NT-proBNP > 3957ng/ml có ty 16 tür vong cao
hon nhiéu so véi nhóm có nóng dó NT- ptoBNP < 3957 ng/ml ( p = 0,001) va
NT- proBNP la yéu tó tiön luromg tir vong dóc lap (Bidu dé 8) [1].

=< 3957 pg/ml

100
=
= 90
i
3 > 3957 pg/mı

70]

ss]

To 35 30

Naay
Biêu dó 8. Xde suät sóng con theo diém edt nóng dé NT-proBNP [1].

FABP)

2.1.7. Heart type Fatty Acid Binding Protein (H-

H-FABP do Giáo su Tién sf Jan Glatz phät hign ra váo mim 1988, Day la

möt loai protein & bao tuong, hign dién cha yéu trong té bio co tim, có 46 nhay

‘cam va dó dic higu cao cho co tim. Nhö có kich thurde rät mhó va trong rong

phan tir thip (13-15000 dalton) nén chi trong vöng 30 phút sau khi co tim bi tén
du [58]

thurong do thidu mäu, H-FABP dä xuát hién ngay trong n

13

ascii com

C6 rät nhièu

ira dá chimg minh vai tró quan trong ca

öng tñinh nghi

H-FABP trong chin doán som nhdi máu co tim cáp cüng nhu trong viéc cung

cp nhiing thong tin có gid tr tién luong manh mé vé nhüng bién có sau nhöi

mau co tim cap [59], [111], [123]. Tuong tu nhu các Troponin tim, nhièu
nghién ciru cho thay méi lién quan thuán gitta nóng dó H- FABP va dién tich
ving nhöi méu [57], (85), 1147]

ML FABP> 8 g/ml.

E 20.

3

E

E fea
ES von tate
: pm

5 do ET 360
Biêu dá 9. Nöng dó H- FABP vá ÿ lé cdc bién có sau NMCT [108]
Trong thir nghiém OPUS-TIMI 16 trén 2287 bénh nhân có höi chimg

vanh cáp, có 332 bénh nhán ting nóng dó H-FABP (> Sng/mL). Thür nghiém

nay cho tháy sur ting nông d6 H-FABP lién quan dén tang ty 16 tir vong va cde
bien có tim mach: NMCT tai phi

10 thing (Bidu dé 9). TY k

ó nhôm có ting H- FABP la
Ty 16 tir vong 6 các mhóm có nóng dó H-FABP < 8 ng/mL, tir 8-16

ng/mL va > 16 ng/mL län lugt 1 3,1%, 6,9% la 18% [108]

Nam 2007, vói thir nghiém EMMACE-2 trén 1448 bénh nhân höi chúmg

vanh cáp, Kilcullen va cóng su dä chimg minh nông dó H-FABP ting la yéu (6,

uy tim sung huyét, trong 30 ngay dáu va

wäl hign các bién có tim mach trong 10 thang däu

5% so v6i mhóm khöng täng lá 9,3% [108]

14

ascii com

quan trong dir báo tir vong sau NMCT. Trong näm däu, ty Ié tir vong nhôm bénh
nhän có nóng dó H-FABP < 5 g/l la 2,1% so vói 22,9% & nhüng truèmg hop

6 ming 46 > 5 up/ [69]. Sau ndy, nghién có cüa Viswanathan, thém mét Hin

ita cho tháy H-FABP có gid tr tin lung dôc lap sau NMCT [137],

25
| “fol +/ He FABP +
20
5 —T Tal -/M-FABP +
£
Fis a
=
2
= 10
5 Tat +/ H- ABP -
‘Tal -/ H- FABP -
o

o 100 300 400

Kay
Biéu dé 10. Nong dé Tal, H- FABP va 6 lé tie vong trong nám dau [78].
Men tim H- FABP cön giúp xäc dinh nhiing déi wrong có nguy co cao
wen tit cá che dai gid tri Troponin I. Véi nhtmg truèng hop có H- FABP va
troponin I âm tinh thi ty 18 tr vong trong 6 thing dáu la 0%. Vói nhümg tring,
hop có H-FABP dung tinh va troponin I 4m tinh thi có nguy co tir vong trong,
nim diu cao (Bién dé 10) (78)
2.1.8. Duöng huyét
Dái thio duróng ting nguy co ti vong tai bénh vién ft mhát 1,5-2 län so vdi
bénh nhän khong dai thio duöng [48], [131]. Dac biét, phu nit kem dai thio
during tién luong xáu hon, gia ting tán suát suy tim sung huyét, nhöi mäu co tim.
46 11) (18), 152}, 162),

ti pt va tig más o tim sau hi ma o tim (Bi

15

ascii om

30

25

20

15

10

Suy tim Séctim | NMCT téi phat” ‘Tir vong

I Gtucoso=< 100 mg/dl Glucose 101-125 mg/dl [E Glucose >= 125 mg/dl
Bi

dó 11. Nong dé ducing huyét va bién có tim mach [52].

18 during huyét phán img có twong quan chit ché véi ty 16 wt vong.
‘Trong nghién cúu góp gm 15 thir nghiém, nóng 46 duöng huyét lic nhäp

vign lién quan véi tinh trang tir vong tai bénh vión va suy tim sau nhöi mäu

136]. Nhüng bénh nhän khéng có dai thao durimg, có nông 46 durong huyét >
6,1-8,0 mml/L có nguy co tir vong gap 3,9 län so voi nhóm khóng có dai
Gurong má náng 48 dudng huyét < 6,1 mmol/L. Nöng 46 dubng huyét > 8,0-
10,0 mmoV/L lim ting nguy co sóc tim va suy tim. Bénh nhán dái thao duóng,
nông dó during huyét > 10,0-11,0 mmol/L thi nguy co tür vong ting vira phai
(nguy co tuong 45% 1,7 Fan),

Trong nghien ei ACOS, trong 5.866 bénh nhán nhdi mau co tim ST
cchénh lén thi 63,1% truimg hop có nóng dé duèmg huyét > 120mg/dL. Nang
46 duöng huyét ting Iie nhäp vién (> 150mg/dL) có ting nguy co tir vong
2,86 län va ede bién có tim mach (tir vong, nhöi mau co tim täi phat, dót quy)
ting 1,88 län [102]

16

Maps éhuyengiaticin com

== 300 mg/dl
E 200- 299 mal

126- 199 mg/at
pro

100- 125 mg/at

o T ? 3 7 3 $
‘Thang

Biéu dd 12. Duóng huyét hic nháp vién vá 4 16 ti vong [125].
C6 nhièu bang chúng vé vige mize duöng huyét cao 6 béni nhân dai thao
during va ting duèmg huyét phán img & bénh nhän khöng dai tháo duèmg lien

quan vói dur haw xáu sau nhdi máu co tim cáp va kiém soát chit ché mise

during huyét có thé mang

loi ich [15]. Dac biét, ting duóng huyét lúc nhâp
vién la yéu tó tién luong xáu. Diéu näy duge chimg minh trong nghién cúu
ren 13.526 bénh nhân hoi chimg vanh cp, nóng d6 duóng huyét léc nhâp
vién 100-125, 126-199, 200-299 vá > 300mg/dL. có nguy co tir vong bénh vién
tuong img 0,73%, 1,24%, 1,87% va 2,34% (Bidu dé 12) [125]. Trong mot

nghién ctu trén 16.871 bénh nhán NMCT cáp, mite duóng huyét > 120mg/dL.
có nguy co tir vong cao vá ting nguy co 1,8 lin möi L0mg/dL. [80]

Bénh nhán nhói mau co tim kém dai thao duöng có du hau xáu hon bénh
nhin Không có dai thio during va kiém sodt mite duóng huyét

duge duy tri sau khi

it ché nen

uit vién. Khuyén cáo cúa ACC/AHA, mue tiéu HbAiC
la < 7%, phù hop vói muc tiêu diéu tri dai théo duöng type 2 [151

2.19. Chite ning thin
Bénh nhân nhöi máu co tim có suy than man hoe bönh than giai doan
ud sé có du hâu xáu. Tam quan trong cúa chite ning thin duge khäo sát qua

nhièu nghién cu [10], [89], [124], [150].

17

ascii com

Phan ch di

trong thir nghigm VALIANT ó 14.527 bénh nhán NMCT
loan chire näng that ıräi hoëc cá hai [10]. Khäo sat 17 16

hp có Kèm suy tim,
tir vong trong 3 näm ó nhüng bénh nhán có ude rang dó loc cáu thn (GFR) >
75, 60-74,9; 45-59.9 va < 45 mViphiit/1,73m? la 14,1%; 20,5%; 289% va
45,5%. Sau khi diêu chinh các yéu 16 nguy co khác, nguy co tir vong hode các
bién có tim mach gia ting có y nghía vói su giám dô loc cáu than (HR = 1,1
mi 10 don vi khi giám dó loc cau thin < 81 ml/phét/1,73m?). Dièu dé cho thay
mire d6 loc cáu thin cáng giäm thi ty 16 tir vong cäng täng (Bidu dé 13.)

Tóng hop tir 130.099 bénh nhán lón tudi nháp vién vi nhôi máu co tim
cp cho tháy suy than có lién quan chat ché véi kha ning söng s6t sau nhdi
mau co tim. Ty Ié tit vong sau 1 näm län lugt IA 24%, 46% va 66% ó bénh
nnhan Không köm suy than (Cr mäu <1,5 mg/dL), suy than nhe (Cr mau tir 1,5-

2.4 mg/dL) va suy thin trung binh (Cr mäu tir2,5-3,9 mg/dL) [124].

Biêu dé 13. Nguy cv ni vong vá dû loc câu thin.

2.1.10. Sé lugng bach chu mau

Tang só luong bach cáu, môt dáu chi diem viém, sé ting các bién có tim

mach va tir vong tai bönh vién, ngin han va lau dai & bénh nhän nhdi miu co

tim cáp [23], (24), [35], [64], [86], [114].

18

ascii om

Dic biát, 1 só bach cáu Neutrophil/Lymphocyte la mt yéu t tién long

tir Vong & bénh nhän nhöi méu co tim cáp ST chénh len rö ráng hon só long
bach cáu chung [107]

Th nghiém TACTICS-TIMI 18 dä chúng minh gi6 ti tión Iuong cúa só
lugng bach cáu 6 bénh nhân NMCTKSTCL hose BINKOD. Só lugng bach
cau täng lién quan vói ty 18 tr vong 6 thang län luot la 1,5%; 3,6% va 5,1% &
nhôm bach câu < 6.650/4L; 6.650-10.110/4L va > 10.110/4L [118].

Trong nghién citu & 153.213 bénh nhán NMCT > 65 tudi cho thiy só

luong bach cau ting lam ting nguy co xuát hién các bién có tim mach lúc
nhâp vién cüng nhur ty 16 tir vong tai bénh vién vá trong 30 ngäy dáu. Trong
nhôm nay, ty 16 ir vong bénh nhân có só long bach cáu cao IA 30,2% so vói
10,3% ó bénh nhán có só lugng bach câu tháp (OR 2,37) [24]. Ó môt nghién
‘cru khác trén 10.288 bénh nan bi nl

ee er re
dau ngue không én dinh, cüng cho thay có möi lién quan chat che git só
lung bach cáu véi ty 16 tirvong trong 30 ngáy dáu (Bidu dé 14)135).

‘Thir nghiém TIMI 10A va B, ty 18 ti vong trong 30 ngày & nhóm bénh
nhán có só lurong bach cáu 5 -10x10°/L, 10- 15 x10°/L va >15 x10%L län lot
la 49%, 3,8% va 10,4% [23]. Só Iuong bach edu cón có y nghía trong tién
ong dai han [67]. 177].

‘Ty vg tog 30 ay (

5 mi 20 25

Sé wong Bach Cau

Bidu dó 14, Lién quan gitta bach cäu vá tit vong trong 30 ngáy dau [35].

19

ascii om

Só luomg bach cáu da mhán trong 24 giö sau can thiép dóng mach vanh

qua da có wrong quan thuán vói kich thuóc ving nhöi méu (r=0,37, D<0,001),
wrong quan nghich vói phán suát tóng máu that tri (r =-0,22, p<0,001) va la
yéu 6 tién luong ddc lap các bién có tim mach [38]

2.1.11. Protein phan üng € dó nhay cao (hs-CRP)

‘Theo Hói Tim mach Hoa Kÿ (AHA) va Trung tim kiém soát dur phöng
bénh tat thi CRP có gid tri rät Ion trong trong tién lwong nguy co các benh tim
mach [133]. Nhö nhüng KT thuât hién nay, CRP dä có thé duge phät hién &
mic nöng dé tháp, goi la hs-CRP.

Nông dó hs-CRP 6 bénh nhán NMCT cáp có khuynh huóng gia ting din
20 nhát 6 gid 48. Nóng dó hs-CRP 6 bénh nhán NMCT cáp cao hon hin so
Gi bénh nhân DTNOP, DTNKOD, nhóm khong bénh PMV [4], [3], (134),

Nghièn cru trén 1.042 bénh nhân NMCTKSTCL, ÿ lé tit vong tai bénh

vién cao 6 nhiing bénh nhan có nóng dó hs-CRP > 10mg/L [101].

Trong thir nghiem TIMI-I1A dánh giä CRP döc lap va phói hop véi

ToT trén bénh nhän hoi chimg vanh cáp, Morrow va cóng sir tháy nóng 46
hs-CRP ting cao trén nhting bénh nhán tr vong trong qué trinh theo di so vi
nhimg truóng hop sóng sót. Nguy co tir vong trong 14 ngäy nhümg nhing,
truéng hop vanh cáp vói CRP > 1,55 mg/dL va CTnT am tinh la 5,8% [93].

Nghién cúu 786 bénh nhán NMCTSTCL cho thiy nóng dó hs-CRP
huyét thanh trong tuong quan déc läp vói ting nguy co tir vong 30 ngay.
Nhóm bénh nhan có nóng dó hs-CRP cao (10,5-74,5 mg/L) ting nguy co tir
vong 30 ngáy hon 1,7 län so vói nhém nông dó tháp (0,1-6.4 mg/L) [531
Nghién cu cúa Oltrona va cs trén 808 bénh nhân NMCTSTCL, gid tri diem
cit tión lugng tir vong 30 ngay cúa nóng dó hs-CRP huyét thanh la > 10 mg/L
vá nguy co tir vong hoje NMCT tang lén 1,9 län [96].

20

ascii om

2.1.12. Thiéu mâu
Su hiën dien tinh trang thiéu mau 6 bénh nhân nhdi mau co tim ST chénh

ten la möt ydu 16 tión long. Trong thie nghiém läm sing trén 14.503 bénh

nhân nhöi mau co tim ST chönh ln, nguy co vé tir vong tim mach trong 30
ngày la 1,21 cho méi Ig/dL giäm cúa Hb khi < 14 g/dL [119]

Tinh trang thidu más Ie nhäp vién hofe sau xuát vién cúng gáy ting
guy co tit vong [19], [92]. Vói nhüng truéng hop có tir phán vi thir ba va thir
tur cia diem GRACE köm thidu mâu thi có nguy co tir vong gáp 2 län so véi

him truóng hop Khóng thiéu méu (Biéw dé 15) 92)

eH
52
E
Ea
7 a
| GF Sesion

* pdm Grace?
Biêu dô 15. Tÿ 16 ti vong theo diem GRACE vá thiéu máu[92J.

Thé nghiém InTIME ILTIMI 17 6 14.373 bönh nhän nhdi mau co tim
cáp ST chénh len, mire Hb < 15 g/dL va CrCl < 100 ml/phôt la yéu nguy co
déc láp vói tinh trang tür vong (nguy co ting 1,22 län cho mói Ig/dL. giám Hb
va 1,23 Lin cho mói 10ml/phút giám CrCl), Chi sé LI (laboratory index= (15 —
Hb) + (100 ~ CrCIVS8) rät có gid tri tién lung vá durge chimg minh qua thir
nghiém EXTRACT-TIMI 25 trén 18.427 bénh nhän (Biéu dé 16) [56].

21

ascii om

177

Ty 19 vong (%)

05 05.20 "20:35 3550 50.70 >70
Chis La

Bidu dd 16. Chi sd LI vá 15 lé tie vong [56].
2.1.13. Roi loan chúc nang that träi
2.1.13.1. Suy tim
Tin suát xuát hién suy tim sau NMCT bién thién tir 30- 40 % [141].
Midi mu co tim |

Tues ook
“en

wg

/ ie oma boat rad Lvene
Guano ve Since on
Taaztos \
CONTENT er o
DECO ie on ns
ES cia J

Ga mach CS mach

Hinh 2. Röi loan chirc náng that trdi sau nhöi mäu co tim

2

Maps éhuyengiaticin com

Co ché suy tim sau nhöi miu duroc t6m tät trong Hinh 2 [71], [51]. Nim
1967, Killip & Kimball nghién ci trén 250 bénh nhán NMCT da cóng bé ty 16

tir vong tüy theo phân dé Killip. Day la bing phan dó don gián dua trén các
triéu chimg lam sang cúa suy tim. Bénh nhän có phán dó Killip cäng cao thi có

85 I6tirvong cáng cao trong 30 ngáy dáu sau NMCT cáp (Bang 3) [79]

“BANG 3 ol

Phan di Ki
DOT Khong có suy tim 6
DOT ‘Suy tim trái, ran 6 phôi 17
DOI Phi phöi 38
Do IV ‘Soc tim 81

Ce nghién ciru sau nay cüng thay ring suy tim (phan 45 Killip II, III)
la yéu 6 tién lurgng quan trong. Trong möt thir nghiém NRMI-2 (the Second
8 bénh nhân NMCT

im theo Killip II hoe

National Registry of Myocardial Infarction) góm 190.
cp, trong dó 36.303 bénh nhán (19%) có phän dó suy

IL có 13 18 ir vong cao hon có y nghia so véi nhém Không suy tim (214% so
%) 11521

Tuong tu, phän tich dir ligu ó 13.707 bénh nhän höi
‘Trung tim GRACE: nhöm Killip I hoe III chiém 13% véi ÿ 18 tú vong bénh
vién ting cao hon nhóm khóng suy tim (12% so véi 2,9%), cing nhur tir vong
sau 6 thang (8,5% so vói 2,8%). Trong nghién cúu nay, nhóm benh nhân tién
trién suy tim sau nháp vién có ty 16 ttt vong bénh vién cao (17,8%) [130].

Ging vanh cáp cia

‘Trong thir nghiém GUSTO-I (1995) cüa Lee KL, Woodlief LH, Topol EJ
va cóng sur trén 41,021 bénh nhán cüng cho két qua tuong tu (Bang 4) [82]. Ö
bénh nhân NMCT cáp có thé xuát hién rói loan chire náng tim thu va tam
trong, Röi loan chite nang tám thu, tám truong trén lam sing có tién long,

xáu hon nhóm khóng có tinh trang sung huyét phöi [26].

23

ps Icngiaachinh com

BANGER (52)

Tj EE = tr = ILLIP

1 85 5,1
u 13 13,6
um 1 322
Vv 1 578

tim va phän suit

Rói loan chite náng tim thu chà yéu anh huóng dén giám cung luong

mg mau, Nhidu thir nghiém lam sing cho thay phän su

tóng máu la yéu 16 dôc láp va quan trong trong dur bao döt tir. Phan suat téng,

198], [99]. Rói loan chúc nang tám thu don dóc sau NMCT la yé

gidm lim ting nguy co döt tir vá nguy co xáy ra rói loan nhip [22]

16 tiên

long ir vong, Nehien city GISSI-2 & 10.219 bénh nhán NMCT séng con

duoc theo dôi tir vong chung trong 6 thang, suy chite näng tim thu that trai

sóm có Wrong quan chat ché véi

nh trang tir vong (RR= 2,41; 95% CI, 1,87-

3,09) (Bidu dó 17) (50), [138]

“Ty 18 tx vong trong 6 thing (%)

3

30- 39%

40-49%

o

Ir

20 3 0 3 © 0
Phin su ting méu thit ri do ren SA( %)

50-59% >=60%

43 17. Phan suát tóng máu that trái va tie vong [50].
24

ascii om

Rói loan chire ning täm tricong din dén ting áp luc tinh mach phéi vi
sung huyét phöi. Tan suát tir vong sau NMCT cáp có lien quan vói su dé diy
tam truong han ché. Tóng hop 16 nghién eiru 6 3.855 bénh nhán NMCT, duroe
theo doi tir 2 tuán dén 5 nám. Két qua: 776 (20%) bénh nhan có han ché 45
diy thit, 580 bénh nhân tir vong (247 bénh nhán có han ché dé day thât) va
nguy co tir vong la 4,1% (Cl 95%, 3,38 - 4,99) [142]

2.1.13.2. Sdc tim

Sóc tim la nguyén nhän tú vong hing däu 6 bénh nhán nhöi mäu co tim
cáp. Tÿ 18 sóc tim chiém tir 5 dén 10% va hai phän ba các trudng hop tit vong
sau vai twin [128].

Se tim la mó bién hión Kim sáng näng nhit cia tin tang suy tht rá

‘BO róng thong tón that träi, khiém khuyét co hoc ching han thúng vách lien

thit, dit co há hode hi mau tht phat wu thé lim ting 4 6 xu

tim [20], [113]. Nhièu yéu tó dur báo xuat hién tinh trang sóc tim: tudi cao,
tión sit nhôi mäu co tim (de biét vüng true), suy tim sung huyét, tin sir dä

théo duèmg, rung nh, tin só tim cao va ngimg tim [26], 1691.

80 701

a
3

Tir vong (%)
5
3

mn
Ss

= —
Bérih vién Sau 30 ngáy
Bigu dó 18. Tinh trang sóc tim va ti vong [45].

Nghién ciu 1.345 bénh nhán nhói mau co tim cáp ST chénh len, có 7,2%

o

25

ascii om

bénh nhán có bién chimg sóc tim. Tir vong trong 30 ngay 6 bénh nhän có bién
7%, p= 0,0005)
‘Tén thurong thin chung dóng mach vanh tréi gäy bién chimg sóc tim cao hon
có y nghia (20,7% so vói 3%, p < 0,0001) (Bid 4618) [45].

chimg sóc tim cao hon nhém khóng sóc tim (11,1% so v

Trong can thiép mach vanh cho qua da, tán suát tir vong & nhümg bénh
mhán nhöi mäu co tim có sóc tim gia ting 6 nhümg truóng hop dong chäy
TIMI thap (9).
2.1.14. Thiéu mau co tim tai phät

Thiéu mau co tim tai phät có thé trigu chimg (dau thát ngue lc nghi hofe
hoat döng nhe) hoëc khöng. Nhiéu nghién cúu chimg minh day là yéu 16 tiên
wong xâu [17], 29}, [471

Nhôï mau co tim tai phat là thuèng gap. Thür nghiém GUSTO-I dänh gid

40.484 bénh nhän nhöi mäu co tim ST chönh lén duge didu tri tiéu soi huyét
‘Thiéu mau co tim tai phat xáy ra 6 8.131 bénh nhán (20%), gdm 4.488 truóng
hop dau thit ngue, 3.021 truóng hop dau thát ngue va thay döi doan ST, 337
truóng hop dau thát ngue va rói loan huyét dóng va 285 trudng hop dau thát
gc, thay déi doan ST va rói loan huyét dóng [29].
‘Thir nghiém náy cúng cho thay ring
— Thigu máu co tim täi phat thwöng gäp 6 gidi nú, có nhièu yéu 16 nguy
co tim mach, it dutoe diéu tri heparin tinh mach va tn thuong dóng
mach vanh nhidu va rong
— TY 16 tú vong trong 30 ngäy va 1 näm ting cao & nhiing bénh nhân có
rói loan huyét dóng, déc biét néu có suy tim.
— Nhôi mau co tim tai phat ting län néu có dau ngue va sé ty 16 may sé
cao hon & nhüng truóng hop có thay dói ren dien tim, rói loan huyét

ding hay cà hai (Bidu dé 19),

26

ascii om

Khong dau neve

E =
2
E

Pau ngye! RL hupér
i + Dav cr Bién abi ST
= a
©

Pau ngyer RL huyét dingy Bién dd ST

3 Y is 20 35 30
Ney

Bigu d 19. Dau hät nguce sau nhdi mäu vá thay döi doan ST trong tién
doin NMCT tai phät (29).
Tuong te, trong nghiën ciru GUSTO-IIb tn 4.125 bönh nhän nhöi mau

co timcáp.có ST chénh lén, thión máu co tim tii phat gáp 23% truóng hop.
100

2” Khóng TMCT
ES

TMCT khang tri

0 60 120 180 240 300 360
Neay

Biéu dö 20. Thiéu máu co tim tái phat vá tÿ 16 song con ) [17].
27

ascii om

‘Trong nhém nay, ty 18 séng cúa nhóm khong nhöi máu va nhöi mäu khong

nhöi mau kháng tri (Bidu dé 20,117].

khang tri cao hon so v

2.1.15. Röi loan nhip tim

Su xuát hi

rói loan nhip trong 24 - 48 gig sau nhöi máu co tim là tién

yong xäu. Réi loan nhip thuróng gáp lá rung nb vá các röi loan nhip that
Rung mhi la dang rói loan nhip trén that thuöng gap sau nhöi mau co tim.

‘Thir nghiém GUSTO-1 góm 40.891 bénh nhän, tán suát rung nhf khoáng 2,5%

lic nhap vién va 7,9% trong thoi gian nim vien. Nhüng bénh nhän rung nht

thudng có tén throng 3 nhanh déng mach vanh va ty 18 tir vong trong 30 ngay
cao hon nhém bénh nhán khöng rung nhi (Bidu dé 21) [41].

Bes
a Rong abt tae
0 o E |

Bidu dó 21. Rung nhi vá ty lé sóng con [41].

Thür nghiém GUSTO-3 & 13.858 bénh nhän sau NMCT, tán suát xuát
hign rung nhf trong thoi gian nim vign IA 6,54%. Tan suát xuát hién nhüng
bién chimg tim mach 6 nhóm nay cüng cao hon nhém khóng có rung nhi vá
guy co tir vong trong 30 ngay la 15% so vói 6% khóng có rung nt [148].

Trong thir nghiém GISSI-3, khäo sát 17.944 bénh nhán nhöi mäu co tim
cáp tong 24 gió dâu. Rung nht kich phát chiém 7,8%. Sau khi higu chinh
nhimg yéu tó nguy co khäc, bénh nhän nhöi mau co tim kém rung nhi có tán

suat tir vong cao cá trong bénh vién (12,6% so véi 5% Không rung nhi) vá sau

28

ascii om

4 nim (nguy co turong déi IA 1,78) [116]. Két qua tuong tu, trong mot nghi
ctra 6 4108 bénh nhán nhöi máu co tim cáp nháp vién tai 16 bénh vién khu
vue [60]. Sr ie

quan gitta rung nb véi ti vong ting län khóng phai la do ban
chat rôi loan nhip, ma la nhéing yéu 16 khée lien quan vói nó, dic biét la suy
tim, söc hoëc rói loan nhip thát nguy him [27], (60).
Rói loan nhip that sau nhöi mau co tim cap bién thién tir ngoai tim thu
that cho dén rung that. Tan suát xuát hién rói loan nhip that gdm:
— Ngoai tam thu that 10.93%,
Nhanh thât 3-39%.
= Rung that 4-20%,
Ngoai tam thu that sém khong lien quan véi tien luong ngán han va iu
‘ai sau nhdi máu co tim. Tuy nhién, ngoai tim thu that da dang kéo dai 48-72

id sau nhöi máu co tim có thé lam ting nguy co rói loan nhip vé sau [30].

Tán suát rung thát cüng duoc ghi nhän trong thir nghièm GISSI-2 &
9.720 bénh nhän. Rung thit sóm (< 4 gib) chiém 3.1%, rung thât muón © 4
dén 48 gid) la 0,6%. Trong dé, rung thät nguyén phat (khöng có suy tim hode
sóc tim) lién quan véi tinh trang tir vong bénh vién [139]. Nhiéu thir nghièm
lim sing xäe dinh mot 155),

1139):
— Ha kali miu

yéu 16 gay ting nguy co rung thát, bao gi

— Huyét äp thap
— Vüng nhöi mau röng.
— Nam gigi
Hüt thude lá
Thir nghiém GUSTO-1 6 40.895 bénh nhân nhöi méu co tim cáp ST

‚chenh len, tÿ 1é rói loan nhip that dang nhanh that hoác rung that chiém 10,2%

29

ascii om

trong dé: 3,5% nhanh thät, 4,1% rung thit va 2,7% nhanh thät va nung thét.
Néu loai tri nhüng truóng hop sóc tim, nhém rung thal/ nhanh that c6 19 16 tir

vong bénh vién cao nhém khéng rung tháW nhanh that (Bang 5)[103).

BANGS. 1103)
‘Réi loan nhip that va 1516 tit von;

Tai bénh vién 92 15,0 284 23
Trong30ngiy 88 15,1 293 21)
Trong 1 nim 144 170 333 53

‘Nhip nhanh that có lién quan vói ting 15 18 ti vong bénh vién la do ngung
tim va lan róng ving nhöi mäu. Thé nghiém TIMI-II, nhip nhanh that hoe
rung thát trong 24 gió dáu chiém 1,9% ma khöng có bing chimg vé tut huyét
áp hode suy tim. Nhüng bénh nhán nay có tán xuát tir vong cao (20,4% so vói
1,6% khöng rói loan nhip that), nhumg khóng có su khác biét vé tinh trang tir
vong muón 6 mhóm bénh nhän sóng cón sau 21 ngay [28]

Nhip nhanh xoang cüng thuèng gäp 6 nhiimg bénh nhân NMCT cap.
‘Ting nhip tim thuróng phan ánh mite dó hoat hóa cúa hé than kinh giao cám.
Nhimg bénh nhän nhôi máu co tim cáp có nhip tim nhanh > 100 län/phit hay
glp à nhimg trröng hop nhöi mau co tim ving tnróc va réng, röi loan chic

näng that trai va có tién long xáu [42].

2.2. CAC THANG DIEM DANH GIA NGUY CO

Taie nhüng nim 1990, nghién cin GUSTO-IIb kháo sát 6 12.142 bénh
nhan höi chimg mach vänh cap: trong só bénh nhán nhói mau co tim ST chénh
ln có 11% nong döng mach, va & nhóm nhöi mäu co tim khéng ST chénh len.

vá dau thit nguc khong én dinh dugc chup mach vánh va tai tuói máu chiém

30

ps Icngiaachinh com

57 va 349%. Tan suat tt vong 6 3 nhóm trong cing thi diem nhır sau

— Ti vong trong 30 ngay: 6,1 (Nhöi mau co tim cáp có ST chénh lén);

5,6 (nhdi mau co tim cáp khong ST chénh lén) vá 2,4% (dau thát nguc
khong ón dinh) .

— Tir vong trong 6 tháng: 8,0-8,8-5,0%.

= Tirvong trong 1 nam: 9,6 -11,1-7,0%.

Ben canh dó, trong kháo sát 10,000 bénh nhân höi chúng mach vanh cáp
& 103 bénh vién cúa 25 quöc gia Chau Au cho tháy: t¥ 16 tir vong bénh vién &
nhôm nhöi máu co tim cáp có ST chénh lén cao hon nhöi máu co tim cáp

1%

khong ST chönh lén tuong img 14% va 12%, vá tir vong trong 30 ng:
vá 7,4%. Nhôm dau that nguc có ty Ié tit vong trong 30 ngäy ıhäp nhât (1,79%).

Tir dé, các nghién ciu Kin dí xäy dimg các thang diem dé tién luong

nguy co tit vong trén mhúng bénh nhán hói chimg mach vánh cáp nhim xáy

img nhüng chién lugo diéu tri tt nhât.

‘Nam 1998, nghién cu nhöi máu co tim ó da trung tám dänh gia dit liéu &
170.143 bénh nhan (có hode khong có ST chénh én) nhim xác dinh nhóm

bénh mhán nguy co cao [26]. Môt só yéu 16 nguy co cao bao gdm: trén 70 tuói
nhôi mau co tim cd, phän dé Killip lúc mháp vién, nhöi máu co tim ving tnróc
va két hop tut huyét áp va mbip tim nhanh.

Trong nghién cin GUSTO & 41.021 bénh nhán, tim thay các yéu (6 tién
long tir vong trong 1 näm bénh nhân nhöi mau co tim söng cón sau 30

ngay [33]

- Yéu 16 nhän tric hoc: tudi, nhe cat

= Ving nhöi máu co tim röng: phân 46 Killip cao, tut huyét äp, nhip tim

nhanh, QRS röng.

31

ascii om

= Yu 16 nguy co tim mach: hat thude lá, ét áp va tai bién mach

Si loan nhip

‘Trén co só nhümg két qua va phán tich các thir nghiém va trung tm lón,
có nhidu thang didm nguy co 48 dinh gid tién long ngán han va dai hen &
bénh nhän NMCT ST chénh len [46], 63], [66], [87], [95], 1971, [136]

êm TIMI

22.1. Thang
Ban dau, chi só nguy co TIMI do Antman va cóng sw phat trién góm 7
yéu 16 dänh gid dänh cho NMCT khöng có ST chénh (Bang 6).

Thang diém TIMI déi voi HCMV edp khong có ST chönh lén

Tuoi > 65 ‘Ting men tim

23 yéu tó nguy co BMV 1 {C6 thay dói doan ST a
iönsichepDMV>50 1
%
Tién ste ding Aspirin? | > 2 com dau thät ngue 1
ngây tuée mháp vién trong vong 24h

Chi só nay dugc dänh gia trong thir nghiém TIMI 11B va nghién ciu
ESSENCE gém 2 nhöm duge dióu tri bing Heparin khéng phan doan va
enoxaparin. Sau dó, dia trön thir nghiém In-TIMI Il tién hanh & 15.000 bénh
nhân, Morrow DA va cong su dua ra chi só TIMI dé tién long tir vong 30
ngäy vá 1 nám cho nhüng bénh nhân NMCT có ST chénh (Bang 7).

‘Thang diém näy dä duc dánh gia trong thir nghiém TIMI- 9. Chi so
‘TIMI có gid tri tién long ngán han va cá dai han: cäng nhiéu chi só nguy co
‘TIMI thi ti 1 tit vong trong 30 ngáy vá sau 1 nim cing ting sau NMCT cáp
[41], 61}, (95).

32

Maps éhuyengiaticin com

Thang diém TIMI döi voi HCMV cáp có ST chönh len
Yéntó Diem
Tudi
64-74
275
HA tám thus 100mgHg
Nhip tim> 1001/p
DO Killip I-IV.
ST chénh len thinh truóc hay block nhnb tr
Tién cin DTD, THA, Dau thit neue
Can näng <67kg
tir lic khöi phät trigu chümg dén khi due,
dé tri tá thong > 4 gib,

‘Thi gi

0-2:nguy corti _3-4: nguy cova _>4:nguy co'cao
Chi só TIMI cing cao thi tin suit xuathign ede bién có (ur vong chung,

nhôi máu co tim méi hofe tdi phát, hode thiéu mau co tim náng cán phai thong,
mach vanh trong 14 ngay) 6 bénh nhán HCVCKSTCL eing exo (Biéu d 22) 13),

45)
= Heparin khong phan doen

sol

| socia
To WA 28,8
de :
de 199 20
Bis! Fan Tan 149

| u

Ma L

“ee E 5 , or

‘Chi s6 TIMI

Biéu dó 22. Diem nguy co TIMI dói voi Höi chieng vanh cáp khong ST
chénh len [131

33

Maps éhuyengiaticin com

Va ty 16 tir vong hoëc nhöi mäu co tim trong 30 ngáy vá 1 näm ó bénh

nhân höi chímg vanh cáp khöng có ST chönh duroc miêu tá & Bidu dé 23.
2] — 1 nam

—— 30 ngay

19,5
157
8.1 = EN
; all
© 0-2 3-4 5-7 TIMI

Biéu dé 23. 7) lé tit vong hoëc nhô máu co tim trong 30 ngäy vá 1
näm à hoi chieng vanh cap khong ST chénh lén theo diém TIMI [61]

a 8

E

Tit vong hoje NMCT( %)

Diém tir 0 dén >8 diem, tién long tir vong trong 30 ngáy lá 0,8-39,5%,
tir vong trong möt näm ö nhüng bénh nhan sóng cón sau 30 ngáy tir 1-16,3%
(Biéu dé 24) (95). Thang diem cüng duoc dänh giä qua thir nghiém lón
NRMI-3 trén 84.029 bénh nhân NMCT [94]
40
as

359
23,
161
124
10 En |
22
A FREE

4
idm TIMI

Tivong 300800)
gR

vong theo dim TIMI 6 HG ching vünh cép ST chénh ln [95].
34

Maps éhuyengiaticin com

2.2.2, Chi só nguy co TIMI
Chi só

nguy co TIMI la mót mó hinh don gián xuát phát tir thir mghiém
InTIME- 6 13.253 bénh nhân nhdi máu co tim ST chénh lén, duge diêu tri
tiéu soi huyét va theo döi trong thöi gian nim vién dé du don ty 16 tir vong
bénh vién. Chi só nguy co TIMI (TRI: TIMI risk index) duroe tinh theo
phuong trinh, chia theo 5 nhém nguy co (Bang 8) [97]:

Nhip tim x [Tuöi/10]°

<125 1 02 06 08
>125-175 2 04 15 19
> 175-225 3 10 31 33
>22,5-30 4 24 65 73
>30 5) 69 158 174

Chi só nguy co TIMI duoc áp dung cho hon 153.486 bénh nhän nhöi
mâu co tim ST chénh lén thuôc Trung tim kiám soát nhdi méu co tim cia Hoa
Kÿ [145]. Nghién ciru cho tháy có méi lièn quan gitta chi só nguy co TIMI vá
phan ting tir vong bénh vién: khoáng 0,6 dén 60% tir diém só thäp (0 - <10
diem) den diem só cao nhát (> 80 diem) & nhümg bénh nhán duge diéu tri tái
ui mau va tir 1,9 — 52,2% trong nhümg bénh nhán khóng duoc tai tdi mäu
[145]. Vai nhüng truóng hop nhöi mäu co tim khóng có ST chénh län, nghién

35

ps Icngiaachinh com

‘cru cia Trung tam kiém soat nhöi máu Hoa Ky cho thay dói véi ede nhôm có
nguy co tháp (TRI < 30) thi 17 18 tir vong tai bénh vién tuong duong véi
NMCT ST chénh. Tuy nhién ty 16 nhém bénh nhán NSTEMI có nguy co trung
binh vá cao ( TRI > 30) thi ty 18 tr vong tháp hon so vói nhém STEMI có hay
Khóng didu tri tai tré méu [146]

2.2.3. Thang diem nguy co MAYO
Môt nghién cüu doán hé göm 1212 bénh nhän nhdi mäu co tim cáp nhap
tir 1988-2000, trong dé 809 dir

liéu bénh mhán true nám 1997 vá 403 det lióu bénh nhán sau 1997. Göm 8

don vi chim sóc mach van tai Mayo Cli

yéu 16 ten Iuomg: tubi, gidi, huyét áp tim thu, creatinin, doan ST, khoáng
QRS, phân dó Killip va ving nhöi mäu (Bang 9) [143]

CHANG. 7 [143]
Thang diém MAYO

nés 2 ST chénh xuöng:
mv a
amv 3
Gin 3 QRS>100ms 1
HA tám thu <140 = Phan dé Killip >1 1
Creainin> 14 di miu ving 1
mg/dl tuée

Biéu dé 25 cho thay ty 16 ti vong trong 30 ngäy ting theo diém só nguy

co 6 cà tap mó hinh va tap xác nhân.

36

ascii om

40

Tóp mó hinh
— Táp xác nhän
2%
ES
320
E 4
10 Ya
7
Men bi
o! + I | L | J
0-1 23 #5 ET 89 10
Diém MAYO

¡éu dá 25. Dióm nguy co MAYO vá 16 tie vong [143].
2.2.4. Thang diém nguy co GRACE
‘Thang diem nguy co GRACE dugc dua wen thir nghióm lón góm
11.389 bénh nhân HCVC [11], 125]. M6 hinh nay dá duge chümg minh trong
thir nghiém GRACE va GUSTO-IIb, cüng nhur các thir nghiém lón & Canada
va BO Bao Nha [11], [25].
C6 8 yéu 16 duge sit dung trong thang diem nguy co GRACE :

‚on tuo

phin d6 Killip, huyét áp tim thu, bién déi doan ST, ngung tim hie nám vién,
ting creatinin huyét than, ting men tim va nhip tim (Báng /0) [11].

Các yéu 1ó nguy co có kha näng tién Irong déc láp vé tir vong bénh nhän
30 ngay va sau 6 thing & bönh nhän NMCTSTCL, NMCTKSTCL hoa
DINKOD [49], [61], [63]. Va dic biét trong mót phán tich tóng hop gin diy

trén 40 nghién cin góc, gdm 216.552 bénh nhân va 42 nghién cüu xác nhän,

gôm 31.625 bénh nhán, dä chimg minh gid tri tién lung rat töt vé cá ngán han
va dai han [43].

37

ascii om

1,7/10 nam

Phan d6 Killip 2,01 m81 do,
Huydt áp tám thu. 1,4/ giám 20 mmHg
Bien dói doan ST 24
'Ngung tim lúc näm vién 43
‘Tang creatinin huyét thank 1,2/ ting Img/dL.
Táng men tim 16

Nhümg mó hinh nguy co dá mó tá 6 trén dupe xáy dung dura trén dir liéu 6
hing bénh nhän nhöi méu co tim cáp due didu tri tu soi huydı. Nhümg mó
hinh nay có thé không áp dung durge & bénh nhán durge diéu tri can thiép dóng
mach vanh nguyén phat. Do dó, khi tiép cán tién Irong bénh nhán NMCT cáp
duge digu tri can thigp mach vanh nguyén phát cin có nhting mó hinh khäc.

Nhièu mó.

'h dä drge tim ra vá duge dänh gia trén nhüng benh mhán
nhöi mäu co tim cáp có can thiép mach vanh nguyén phät: chi só nguy co
Zwolle, thang diém nguy co CADILLAC vá thang diám nguy co PAMI
2.2.5. Chi só nguy co Zwolle

Chi só nguy co Zwolle dua trén dir tigu cúa 1791 bénh nhân NMCT ST
chénh diêu tri nong döng mach vanh qua da & Zwolle, Ha lan tir nim 1994-
2001 [46]. Tat cá bénh nhân duoe diéu tri vi aspirin va heparin, va 50% có
it stent dóng mach vänh vá wafarin (truée 1996) ho%e ticlopidine hay
clopidogrel (sau 1996). Ty 18 tt vong trong 30 ngäy däu la 3,6%. Mot só yéu
16 nguy co dóc lap có y nghía trong tión hong tir vong 30 ngäy duroe thiét lap
trong chi só nguy co Zwolle bao gôm: phan dé Killip, phán dó dong cháy

‘TIMI sau can thigp mach vanh qua da, t lóng mach vanh tón thuong, vi

38

Maps éhuyengiaticin com

trfnhdi mâu, va ıhöi gian thiéu méu, nhói mau vüng truóc (Báng 11) [46]

Chi só nguy co Zwolle duge kiém chimg qua di ligu 747 bénh nhân nhöi

mâu co tim ST chönh lén duge diéu tri can thiép mach vánh qua da nguyén

phat tir thing 10/2001 dén thang 2/2003.

146]
E co Zwolle
Phan dp Killip Tón thucong 3 nhénh
1 o Bu! &
2 4 CM 4
za a Khong
Dang cháy TIMI Nhöimäu ving rude
sau PCL có 1
3 o Khong 0
2 1
0. 2
Tuói Thói gian thión mau ( <
<6 o agi) 1
260 2 oo
Khong
Dura váo chi só nguy co Zwolle, hon 2/3 bénh nhän duge can thiép mach

vänh qua da có nguy co tháp (diém nguy co < 3). Ty Ié tür vong ö nhóm bénh

nhân nay 12 0,1% trong vong 2 ngäy va 0,2% ngay trong vöng 2-10 ngay sau

nhôi mau co tim (Bidu dé 26) [46]. Tir dó dura ra kién nghi: nhürng benh nhän

nguy co tháp có thé xuat vién som mót cách an toan (48 gid sau can thiép).

39

ps Icngiaachinh com

53

ss
yes

Em

an ma]
s 221,08 E
nz | sl ll

Biéu dé 26. Tÿ lé tit vong theo chi sé nguy co Zwolle [46].
2.2.6. Thang diem nguy co CADILLAC
M hinh nguy co can thiép dóng mach vänh qua da thir hai duge xuát
phat tir möt thir nghiém CADILLAC & 2082 bénh nhän trong nghién ciru so
sänh abciximab hoie placebo vá dat stent hoëc nong dóng mach vanh qua da
vá duge dänh

4 thang diém qua dir liéu 900 bénh nhán trong thir nghièm
Stent-PAMI [66]. Thang diem nguy co CADILLAC bao góm 7 yéu 16 vá duge
chia thinh 3 nhôm nguy co (Bang 12) 1661
ENG (661
em diem zus CADILLAC
EF 40%
Killip 23
Suy than (Cler <60mV/phiit)
TIMI sau PCL 0-2
Tudi >65
‘Thigu máu (Het: nam <39, nik <36%)
‘Tén thuong 3 nhénh DMV

40

Maps éhuyengiaticin com

Nehi

citu cho thay ty 18 tir vong trong 30 ngay dáu va trong 1 nám dáu

cao dan theo nhém nguy co (Biéu d 27) 166].

3 15
= £
£ al ©
5 EN
a 4
À ER
cm
ces = on =
E seen pam CADILLAC
ión dá 27. Ty 16 te vong theo thang didm CADILLAC [66].

2.2.7. Thang diém nguy co PAMI

Qua nghién ciru 3.252 bénh nhän nhói máu co tim cáp ST chénh lén duge
can thigp döng mach vanh qua da trong thir nghiém PAMI (Primary
‘Angioplasty in Myocardial Infarction trials) (Bang 13). Thang diém nguy co
PAMI có lién quan chit ché vói tinh trang tir vong bénh vién, 1 thing, 6 thang
va 1 nim (Biéu dé 28). Tir diem 0 diém PAMI dén PAMI > 9, nguy co tir
vong trong 6 thing tng dán dén 33 län (p < 0,0001) [6].

16)
Thang diém PAMI

NETA Diém

Tubic
>75
65-75

Phan d6 Killip >1

Nhip tim > 100 Vp

Däi théo duóng

INhöi mau ving truóc hode block nhänh tréi

a

ps éhuyengiaticin com

Trong dé, nguy co tháp (0-1 diem), trung binh-thäp (2-3 diem), tung
binh-cao (4-6 diém) va cao (> 7 diem),

2 + Tai bénh vién
+1 thing
20 + 6 thang
| nám
Ss.
5
3
3
510
E
5
0
0-1 24 5-6 7-8 >9
‘Thang diém nguy co PAMI

Biêu dô 28, Thang diém nguy co PAMI vá th 18 te vong öbönh nhän STEMI

2.2.8. So sánh cic thang diem dänh giá nguy co

Gi tri tin Iuong cüa thang dim TIMI, CADILLAC vá GRACE doc
so sänh ine

Ip trong möt thir

¡ém trén 855 bénh nhán mhói mäu co tim
cáp có ST chénh len, không có sóc tim va duge diêu tri bang can thiep dóng
mach vánh qua da [84]. Theo döi va ghi nhán

bién có tim mach (xr vong,
nhdi mau co tim va tai hep döng mach vánh) Thang diem TIMI va
CADILLAC có tuong quan chat ché vá tién lugng tir vong chính xác trong 30
ngiy vá 1 nim. Mé hinh nguy co GRACE chua chinh xäc.

42

ascii om

So sänh các thang diém dánh gid nguy co

Ti vong 30ngay 0.724 0742 0.824
NMCT30ng’y 0.61 0.64 0.685
Bién có tim
meh os 0.65 0.714
30 ngày
Tirvong nim 0747 0.752 0813

0471

0.533

0.544

0.475

Phan ting nguy co (thäpftrung binh/cao) theo các thang diem
CADILLAC, TIMI va PAMI, các bién có tim mach gia ting có $ nghía vá phú

hop vói thang diém. Tuy nhien, mó hinh nguy co GRACE chua có sw phân

ng ró rêt cäc nguy co.

43

ps Icngiaachinh com

II. KET LUAN

Viéc tién long, dánh gia các yéu tó nguy co trén bénh nhän nhöi mâu
co tim cáp dóng vai tr cue ky quan trong trong viéc quyét dinh phuong pháp
xir tr, theo di bénh va du hau.

Chién luge dánh gia nguy co trén bénh nhân có thé áp dung váo nhidu

thoi diem khäc nhau nhur giai doan cap cúa nhói mau co tim, lúc nim vién va

sau khi xuat vién.

Nhidu cöng tinh nghién cu dä chimg minh các yéu t6 nguy co có lien

quen dén che bién cb tim mich va ti vong bao gm:
+ Che yéu tó nguy co hic nhip viga:
+ Lon tuôi

= Nhöi mäu vung trade

6 chuyén dao chénh cúa ST cang cao, kèm sóng QS ca hoai tir
xuyén thanh
- Tang cao men tim: CK-MB, Troponin, NT pro BNP, H-FABP
- Tang duöng huyét lic mháp vién hoÿc dai thio duöng.
- Suy giám chúr näng than.
= Tang bach chu vá dic biét lá ty I Neutrophil/ Lynphocyte.
= Tinh trang thidu miu.
+ Réi loan hofe giäm chüre nang that tri.
+ Thiéu mäu co tim tai phät
+ Rói loan nhip that hoëc trén thit: rung that, nhanh that vá rung nb

‘Tong hop các yéu 16 trén, nhièu nghién cúu dá xáy dung vá dánh gid các
thang diem nguy co dua trén nhüng tham só trong giai doan cáp truúc khi tái

tui méu nhu thang diem TIMI, thang diém nguy co MAYO vá mó hinh nguy

44

ascii om

co GRACE.
a
nguy co PAMI duoc

à thang diem

i s6 nguy co Zwolle, thang diem nguy co CADILLAC

y dung dé phän ting nguy co som ó bénh nhän nhöi

mau co tim cap ST chénh ln. Nhümg bénh nhán nguy co cao sé duge dièu tri
bing can thigp dong mach vanh qua da som göp phán lam giám ty 16 tir vong
va các bién có tim mach sau nhói mau co tim cáp ST chénh lén.

Su hiéu biét vé các yéu tó tién long va các thang diém tién luong sé

6p phn xäy dung chién lugo diéu tri thích hop dói vi timg mite 46 nguy co

nim han ché ci thigu nhiing bién chimg nguy hai vá mang la higu qua dièu
tri tói uu cho bénh nhân.

45

ascii om

TAI LIEU THAM KHAO.

A. TIENG VIET

1, Trin Viét An (2011), " Nghién cúu vai tr cúa NT- pro BNP huyét thanh

trong dánh gid tón thuong dóng mach vänh vá tién long hói ching vanh

cáp", Luán dn tién stY hoc - Dai hoc Y Dugc Hué.
‘Trin Van Huy (2007), “Ty 18 nguy co bénh tim mach 6 ngudi lón Khänh
Hoa theo biêu dó dur bäo nguy co toán thé cha Té chite Y té thé gigi”

3. Trán Thi Kim Thanh (2006), “hs-CRP trong nhdi mau co tim cáp”, Luán
Gn chuyén khoa 2- Truóng Dai Hoc Y Duge Thanh phé Hé Chí Minh.

4. LB Thi Bich Thuan (2005), “Nghién cún sr bién d8i Protein phan img C

STY hoc - Dai hoc Y Dugc Hué.

trong béni mach vänh”, Ludn dn ti
5. Nguyn Quang Tuan (2014), “Nhói máu co tim cáp có ST chönh len’

B. TIENG ANH

6. Addala S, Grines CL, Dixon SR, et al (2004), "Predicting Mortality in
Patients With ST-Elevation Myocardial Infarction Treated With Primary
Percutaneous Coronary Intervention (PAMI Risk Score)", Am J Cardiol,
93, pp.629-632.

7. Alan S. G, Dariush M, Véronique L.R (2014), “Statistical Update Heart
Disease and Stroke Statistics- 2014 Update: A Report From the

American Heart Association”, Circulation, 129, pp.e28-e292,

8. Alhadi HA, Fox KA.(2004), “Do we need additional markers of myocyte
necrosis: the potential value of heart fatty-acid-binding protein”, Q/M,
9704), pp.187-198.

ascii om

10.

Ana Garcia-Alvarez, Dabit Arzamendi, Pablo Loma-Osorio, et al(2009),
"Early Risk Stratification of Patients With Cardiogenic Shock

Complicati
Coronary Intervention", Am J Cardiol, 103(8), pp.1073-1077.
Anavekar, NS, McMurray, JJ, Velazquez, EJ, et al (2004), "Rela

1g Acute Myocardial Infarction Who Undergo Percutaneous

between renal dysfunction and cardiovascular outcomes after myocardial
infarction”, N Engl J Med, 35, pp.1285- 1295.

Anderson JL, Adams CD, Antman EM (2007), “ACC/AHA 2007
Guidelines for the management of patients with unstable angina’ non-ST-
elevation myocardio infraction”, J Am Coll Cardiol, 50 (7), pp.2549-2569.
‘Andrews J, French JK, Manda SO, White HD (2000), “New Q waves on
the presenting electrocardiogram independently predicts increased
cardiac mortality following a first ST-elevation myocardial infarction”,
Eur Heart J, 21, pp.647-6:
Antman EM, Cohen M. and Bernink P.J (2000), “The TIMI rick score

for unstable angina/non-ST elevation MI: a method for pronostication
and therapeutic decision making”, JAMA, 284 (7), pp.835-842.

Antman EM, Tanasijevic MJ. and Thompson B (1996), “Cardiac-
specific troponin I levels to predict the rick of mortality in patients with

acute coronary syndromes”, N Eng J Med, 335, pp.1342-1349,

Antman, EM, Armstrong, PW, Green, LA, et al (2004), "ACC/AHA
Guidelines for the Management of Patients With ST-Elevation
Myocardial Infarction”, J Am Coll Cardiol, 44(3), pp.e-e211

‘Arakawa NI, Nakamura M, Aoki H, Hiramori K. (1994), Relationship
‘between plasma level of brain nature peptide and myocantial infarct size.
Armstrong, PW, Fu, Y, Chang, W-C, et al, for the GUSTO-IIb

ascii om

Investigators (1998), "Acute coronary syndromes in the GUSTO-IIb trial:
Prognostic insights and impact of recurrent ischemi
pp. 1860-1868.

18, Aronson D, Rayfield El, Chesebro JH (1997), "Mechanisms determining

Circulation, 98,

course and outcome of diabetic patients who have had acute myocardial
infarction", Ann Intern Med, 126, pp.296-306.

19. Aronson D, Suleiman M, Agmon Y, et al (2008), "Changes in
haemoglobin levels during hospital course and long-term outcome after
acute myocardial infarction”, Eur Heart J, 28, pp.1289-1296.

20. Babaev, A, Frederick, PD, Pasta, DJ, Every, N, Sichrovsky, T, Hochman,

JS (2005), "Trends in management and outcomes of patients with acute

‘myocardial infarction complicated by cardiogenic shock". JAMA, 294(4),
pp448-458
21. Barbash G.1, Reiner J, and et al (1995), “Evaluation of the paradoxic

beni

ial effects of smoking in patients receving thrombolyti

therapy
for acute myocardio infarction: Mechanism of the “smoker's paradox
from the GUSTO-I trial”, J Am Coll Cardiol, 26 (5), pp.1222-1229.

22, Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et
al..(2005), “Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

Investigators. Amiodarone or an implantable cardioverter-defibrillator for
congestive heart failure”, N Engl J Med, 352, pp.225-237,

23. Barron HV, Cannon CP, Murphy SA, et al (2000), “Association between
white blood cell count, epicardial blood flow, myocardio perfusion, and

clinical outcomes in the setting of acute myocardio infraction: A

: Circulation, 102,

24. Barron HV, Harr SD, Radford MJ, et al (2001), “The association between

ascii om

25.

29.

30.

white blood cell count and acute myocardio infraction mortality in
patients > 65 years of age: findings from the Cooperative Cardiovascular
Project”, J Am Coll Cardiol, 38, pp.1654-1661

Bassand JP, Hamm CW, Ardissino D, et al (2007), “Guidelines for the
diagnosis and treatment of non-ST-segment elevation acute coronary
syndromes: the Task Force for the Diagnosic and Treatment of Non-ST-
‘Segment Elevation Acute Coronary Syndromes of the European Society
of Cardiology”, Eur Heart J, 28, pp.1598-1660.

Becker, RC, Burns, M, Gore, JM, et al, for the National Registry of
Myocardial Infarction (NRMI-2) Participants (1998), "Early assessment

and in-hospital management of patients with acute myocardial infarct

at increased risk for adverse outcomes: A nationwide perspective of
current clinical practice", Am Heart J, 135 (5 ptt), pp.786-796.
Behar, S, Zahavi, Z, Goldbourt, U, Reicher Reiss, H (199:

Long-term
prognosis of patients with paroxysmal atrial fibrillation complicating
acute myocardial infarction. SPRINT Study Group", Eur Heart J, 13 (1),
pp45-50.

Berger, PB, Ruocco, NA, Ryan, TJ, et al (1993), "Incidence and

significance of ventricular tachycardia and fibrill

n in the absence of
hypotension or heart failure in acute myocardial infarction treated with
recombinant tissue type plasminogen activator: Results from
‘Thrombolytics in Myocardial Infarction (TIMI) phase II trial", J Am Coll
Cardiol, 22 (7), pp.1773-1779.

Betriu, A, Califf, RM, Bosch, X, et. al, for the GUSTO-I Investigators
(1998),
clinical findings", J Am Coll Cardiol, 31(1), pp.94-102.

Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, et al. (1977), “Ventricular

ecurrent ischemia after thrombolysis: Importance of associated

ascii om

31

3.

34,

35.

36.

37,

arrhythmias in ischemic heart disease: mechanism, prevalence,
significance, and management”, Prog Cardiovasc Dis, 19, pp.255-300.
Boersma E, Pieper KS. and Steyerberg EW. (2000), “Predictors of
outcome in patients with acute coronary syndroms without persistent ST-
segment elevation. Results from an international trial of 9461 patients.
‘The PURSUIT Investigators”, Circulation, 101, pp.2557-2567.

Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley
G. A, (1999), Randomized study of the prevention of sudden death in
patients with coronary artery disease. Multicenter Unsustained
Tachycardia Trial Investigators, N Engl J Med, 341, pp.1882-1890.

Califf, RM, Pieper, KS, Lee, KL, et al, for the GUSTO-I Investigators
(2000), "Prediction of 1-year survival after thrombol)
infarction in the Global Utilization of Streptokinase and TPA for Occluded
Coronary Arteries Trial”, Circulation, 101 (19), pp. 9,

Campbell DJ, Mitchehill KI, Schlicht SM et al.(2000), “Plasma amino-

is for acute myocardial

terminal pro brain natriuretic peptid: anovel approach to the diagnosis of
cardiac dysfuntion”, Jcard Fail, 6, pp. 130-139.

Cannon, CP, McCabe, CH, Wilcox, RG, et al, for the OPUS-TIMI 16
Investigators (2001), "Association of white blood cell count with
increased mortality in acute myocardial infarction and unstable angina
pectoris", Am J Cardiol, 87 (9), pp.636- 639.

Capes SE, Hunt D, Malmberg K, Gerstein HC (2000), " Stress

hyperglycemia and increased risk of death after myocardial infarction in
patients with and without diabetes: a systematic overview", Lancet, 355,
pp. 773-778.

Cheung BMY, Kumana CR. (1988), “Natriuretic peptide, relevance in
cardiac disease” JAMA, 280, pp. 1983-1984.

ascii om

38,

39,

40.

41

43,

Chia S, Nagumey JT, Brown DF, et al (2009), "Association of Leukocyte
and Neutrophil Counts With Infarct Size, Left Ventricular Function and
Outcomes After Percutaneous Coronary Intervention for ST-Elevation
337.

Myocardial Infaretion”, Am J Cardiol, 103, pp.3
Christian W.H, Christopher H, Erling F et Keith A.A.F (2006 ), “Acute
Coronary Syndromes: Pathophysiology, Diagnosis and Risk Stratification”,
The ESC Textbook of Cardiovascular Medicine, pp.333-360.

Committee on Preventing the Global Epidemic of Cardiovascular
Disease: Meeting the Challenges in Developing Countries
Global Health, Institute of Medicine (2010), *

Board on

pidemiology of
Cardiovascular Disease”, Promoting Cardiovascular Health in the
Developing World: A Critical Challenge to Achieve Global Health,
National Academies Press (US), pp:49- 124.

Crenshaw, BS, Ward, SR, Granger, CB, et al, for the GUSTO-1 Trial
arial fibril

Investigators (1997),
: The GUSTO-I experience", J Am Coll Cardiol, 30 (2), pp.

ion in the setting of acute myocardial

infarc
406-413,

Crimm, A, Severance, HW Jr, Coffey, K, et al (1984), "Prognos
significance of isolated sinus tachycardia during first three days of acute
myocardial infarction", Am J Med, 76 (6), pp:983-988.

D'Ascenzo F, Biondi-Zoccai G, Moretti C, et al. (2012), “TIMI, GRACE

and alternative risk scores in acute coronary syndromes: a meta

alysis
of 40 derivation studies on 216,552 patients and of 42 validation studies
on 31,625 patients”, Contemp Clin Trials, 33, pp.507-514.

David A. Morrow et al.(2003), “Evaluation of B-Type Natriuretic
Peptide for Risk Assessment in Unstable Angina/Non-ST-Elevation
Myocardial Infarction B-Type Natriuretic Peptide and Prognosis. in

ascii om

45,

46.

41.

4.

50.

51

TACTICS-TIMI 18”, J Am Coll Cardiol, 41(8), pp.1264-1272
De Luca G, Stefano Savonittob, Cesare Grecoc, et al (2008),

"Cardiogenic shock developing in the coronary care unit in patients with

ST-elevation myocardial infarction’
Medicine, 9, pp. 1023-1029.

Journal of Cardiovascular

De Luca, G, Suryapranata, H, van't Hof, AW, et al (2004), * Prognostic

assessment of patients with acute myocardial infarction treated with

primary angioplasty: implications for early discharge ", Circulation, 109
(22), pp. 2737-2743.
Deedwania, PC (1993), "Asymptomatic à

hemia during predischarge
Holter monitoring predicts poor prognosis in the postinfarction period",
Am J Cardiol, 71 (10), pp. 859-861.

Donahoe SM, Stewart GC: MeCabe CH, et al (2007), "Diabetes and
Mortality Following Acute Coronary Syndromes", JAMA, 298, pp. 765-775.
Eagle, KA, Lim, MJ, Dabbous, OH, et al (2004),

validated predic

of 6-

model for all forms of acute coronary syndrome: estimating the
month postdischarge death in an international registry", JAMA, 291 (22),
pp. 2727-2733,

Elliot M. Antman and David A. Morrow (2012), "ST-Elevation
Myocardial Infarction: Management”, Braunwalds Heart Disease: A
Textbook of Cardiovascular Medicine, 9t ed, pp. 1111-1170.
Elliot’ M. Antman, (2012), “ST-Segment Elevation Myocı

Infarction: Pathology, Pathophysiology, and Clinical Features”
Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9h
ed, pp.1087-1177.

Fefer P, Hod H, Many J, et al (2008), "Comparison of Myocardial

Reperfus s With Fasting Blood Glucose < 100, 101 to 125,

on in Patien

ascii om

53.

54,

55.

56.

57

58,

and > 125 mg/dl and ST-Elevation Myocardial Infarction With
Percutaneous Coronary Intervention”, Am J Cardiol, 102, pp. 1457-1462.
Foussas SG, Zairis MN, Makrygiannis SS (2007), “The significance of

circulating levels of both cardiac troponin I and high- sensitivity C
reactive protein for the prediction of intravenous thrombolysis outcome
in patients with ST-segment elevation myocardial infarction”, Heart, 93,
pp.952-956.

Galla, JM, Mahaffey, KW, Sapp, SK, et al (2006), “Elevated creatine
kinase-MB with normal creatine kinase predicts worse outcomes in
patients with acute coronary syndromes: Results from 4 large clinical
Am Heart J, 151, pp. 16-24.

Gheeraert, PJ, De Buyzere, ML, Taeymans, YM, et al (2006), "Risk

factors for primary ventricular fibrillation during acute myocardial

infarct
p.2499-2510.
Giraldez R, Sabatine MS, Morrow DA, et al (2009), "Baseline

: a systematic review and meta-analysis", Eur Heart J, 27,

hemoglobin concentration and creatinine clearance composite laboratory

index improves risk stratification in ST-elevation myocardi
Am Heart J, 157, pp. 517-524.

Glatz JF, Kleine AH, Van Nieuwenhoven FA, Hermens WT, Van
Dieijen-Viser MP, Van der Vusse GJ.(1994), “Fatty acid-binding protein
as a pla
humans”, Br Heart J, 71, pp.135-140

Glatz JF, Van Bilsen M, Paulussen RJ, Veerkamp JH, Van der Vusse GJ,

ma marker for the estimation of myocardial infarct si

Reneman RS (1988), “ Release of fatty acid-binding protein from
isolated rat heart subjected to ischaemia and reperfusion or to the calcium
paradox”, Biochim Biophys Acta,96, pp.1 148-1152.

ascii om

59.

60.

61

62

63.

65.

66.

Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-
ing prot

early detection of acute myocardial infarction”, Clin Chim Acta, 272,

pp87-92.

Goldberg, RJ, Seeley, D, Becker, RC, et al (1990), "Impact of

fir

Visser MP, Hermens WT (1998), “Fatty acid-bin and the

jon on the in-hospital and long term survival of patients with an
acute myocardial infarction: a community wide perspective”, Am Heart
J, 119 (5), pp. 991-1001.

Goncalves PA, Ferreira J, Aguiar C and Seabra- Gomes R (2005), “TIMI,
PURSUIT, and GRACE rick scores: sustained prognostic value and
ineraction with revascularization in NSTE-ACS”, Eur Heart J, 26,
pp.865-872.

Granger CB, Califf RM, Young S, et al (1993),

‘Outcome of patients

n treated with

with diabetes mellitus and acute myocardial infarct

thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial
Infarction (TAMD Study Group",J Am Coll Cardiol, 21, pp. 920-925.
Granger CB, Goldberg RJ, Dabbous O, et al (2003), “Predictors of
hospital mortolity in the Global Registry of Acute Coronay Events”, Arch
Intern Med, 163, pp.2345-2353.

Grau, AJ, Boddy, AW, Dukovic, DA, et al (2004), "Leukocyte count as

an independent predictor of recurrent ischemic events", Stroke, 35(5), pp.
1147-1152.

Hajj-Ali, R, Zareba, W, Ezzeddine, R, Moss, AJ (2001), "Relation of the
leukocyte count to recurrent cardiac events in stable patients after acute
myocardial infarction", Am J Cardiol, 88 (11), pp. 1221-1224.

Halkin, A, Singh, M, Nikolsky, E, et al (2005), "Prediction of mortality

after primary percutaneous coronary intervention for acute myocardial

ascii om

infarction: the CADILLAC risk score", J Am Coll Cardiol, 45 (9), pp.
1397-1405.
67. Halkin, A, Stone, GW, Grines, CL, et al (2006), "Prognostic implic

of creatine kinase elevation after primary percutaneous coronary
intervention for acute myocardial infarction”, J Am Coll Cardiol, 47 (v5),
pp.951-961

68. Hall C., Cannon C.P., Forman $., Braunwald E. (1995), “Prognostic
value of N-terminal proatrial natriuretic factor plasma levels measured

within the first 12 hours after myocardial infarction, ‘Thrombolysis in
Myocardial Infarction (TIMI) II Investigators”, J Am Coll Cardiol, 26,
pp.1452-1456.

69. Hamza H.A, Frederick A. A (2012), “Cardiogenic shock complicating
acute coronary syndromes: Insights from the Global Registry of Acute
Coronary Events”, Am Heart J, 163, pp:963-971.

70. Hillis LD, Forman S and Braunwald E (1990), “Risk stratification before
thrombolytic therapy in patiens with acute myocardio infraction”, J Am
Coll Cardiol,16, pp.313-315.

71, Hochman, Judith S. (2003), "Cardiogenic Shock Complicating Acute
‘Myocardial Infarction: Expanding the Paradigm", Circulation, 107 (24),
pp. 2998-3002

72. James A. de Lemos, M.D., David A. Morrow (2001), “The Prognostic
Value of B-Type Natriuretic Peptide in Patients with Acute Coronary
Syndromes”, N Engl J Med, 345 (14), pp.1014-1021.

73. Jernberg T (2008), NT-proBNP in Acute Coronary Syndromes, NT-
proBNP as a biomarker in Cardiovascular Disease, Thomson Reuters, pp.
101-113,

74, Jemberg T, Stridsberg M, Venge P and Lindahl B (2002), “N-Terminal

ascii om

75,

76.

77

78,

79,

80.

sl

Pro Brain Natriuretic Peptide on Admission for Early Risk Strat
of Patients With Chest Pain and No ST-Segment Elevation”, J Am Coll
Cardiol, 40, pp 437-445.

Johanson P, Fu Y, Wagner GS, et al (2009), "ST Resolution 1 Hour After

sion

Fibrinolysis for Prediction of Myocardial Infarct Size: Insights from
ASSENT 3", Am J Cardiol, 103, pp. 154-158.

Jonas. Hallen (2012), “Troponin for the Estimation of Infarct Size: What
: Cardiology, 121, pp:204-212.

Have We Learned ?
Julio NáñezLorenzo Fäcila et al(2005), “Prognostic Value of White
Blood Cell Count in Acute Myocardial Infarction: Long-Term
Mortality”, Rev Esp Cardiol, 58 (8), pp: 631-639.

Kilcullen NI, Viswanathan K et al (2007), “Heart-Type Fatty Acid-
Binding Protein Predicts Long-Term Mortality After Acute Coronary
Syndrome and Identifies High-Risk Patients Across the Range of
‘Troponin Values”, J Am Coll Cardiol, 50 (21), pp2061-2067

Killip T 3d, Kimball 3T.(1967), “Treatment of myocardio infraction in a
coronay care unit. A two year experience with 250 patients”, Am J
Cardiol, 20, pp.457-464.

Kosiborod M, Inzucchi SE, Krumholz HM, et al (2008), "Glucometries in
Patients Hospitalized With Acute Myocardial Infarction Defining the Optimal
Outcomes-Based Measure of Risk”, Circulation, 117, pp. 1018-1027.
Lawrence J. L., Peter A. (2012), “The Worldwide Environment of

Cardiovascular Disease:Prevalence, Diagnosis, Therapy, and Policy
Issues.A Report From the American College of Cardiology”, J Am Coll
Cardiol, 60 (suppl S), pp-S1- $49.

Lee KL, Topol El et al (1995), * Predictors of 30-day mortallity in the
era of referfusion for acute myocardial infraction. Results from an

ascii om

83

85.

86.

87.

88,

89.

international trial of 41, 021 patients GUSTO Investigators”
Circulation, 91, pp.1659-1688.

Lee KL, Woodlieg LM, Topol EJ, Weaner D, Bertrin J, Califf RM
(1995),

redictors of 30 day mortality in the era of reperfusion for acute
‘myocardial infarction. Results from intemational trial of 41,021 patients.
", Circulation, 91,pp. 1659-1663.

Lev, El, Komowski, R, Vaknin-Assa, H, et al (2008), "Comparison of the
Predictive Value of Four Different Risk Scores for Outcomes of Patients
With ST-Elevation Acute Myocardial Infarction Undergoing Primary
Percutaneous Coronary Intervention”, Am J Cardiol, 102 (1), pp. 6-11.
Levine RS, Alterman M, Gubner RS, Adams EC Jr.(1971), "Myoglobinuria
in myocardial infarction”, Am J Med Sci, 262, pp.179-183

Madjid, M, Awan, I, Willerson, JT, Casscells, SW (2004), "Leukocyte
count and coronary heart disease: implications for risk assessment", J Am
Coll Cardiol, 44 (10), pp. 1945-1956.

Marchi iF, Bar
risk of death after myocardial infarction by use of multiple-risk-factor

R, Avani F, et al (2001), "Assessment of absolute

assessment equations: GISSI-Prevenzione mortality risk chart", Eur Heart
J.22( 22), pp. 2085-2108.

Martinez-Rumayor A, Richards AM, Burnett JC et al (2008), Biology of
the Natriuretic Peptides, AM J Cardiol, 101[suppl], pp-3A-BA.
McCullough, PA, Nowak, RM, Foreback, C, et al (2002), "Emergency

evaluation of chest pain in patients with advanced kidney disease”, Arch
Intern Med, 162 (21), pp. 2464-2468.

Melanie N. Nick T., Peter S., Mike R. (2013), Cardiovascular disease in
Europe: epidemiological update, European Heart Journal, 34(39), pp.
3028-3034.

ascii om

91

92

93

95.

96.

97,

98,

Melanie Nichols, Nick Townsend, Peter Scarborough et Mike Rayner

(2012), “European Cardiovascular Disease Statistics”, British Heart
Foundation Health Promotion Research Group, Department of Public
Health, University of Oxford,

Meneveau N, Schiele F, Seronde MF, et al (2009), "Anemia for Risk

Assessment of Patients With Acute Coronary Syndromes", Am J Cardiol,
103, pp. 442-447,

Morrow DAA et al. (1998), “C-Reactive Protein Is a Potent Predictor of
Mortality Independently of and in Combination With Troponin T in
Acute Coronary Syndromes: A TIMI 11A Substudy”, Journal of the
American College of Cardiology, 31(7), pp.1460-1465.

Morrow DA, Antman EM , Parsons L, et al (2001), “Application of the
TIMI Risk Score for ST- Elevation MI in the National Registry of
Myocardio Infarction 3”, JAMA, 286, pp.1356-1
Morrow DA, Antman EM, Charlesworth A, et al (2000), “TIME risk

score for ST-elevation myo infraction: a convenient, bedside, clinical
score for risk assessment at presetation: an intravenous nPA for treatment
in infracting myocardium early II trial substudy”, Circulation, 102,
pp2031-2037.

Morrow DA, Cannon CP, Jesse RL et al (2007), “National Academy of
Clinical Biochemistry Laboratory Medicine Practice Guidlelines:

Clinical Characteristics and Utilization of Biochemical Marker in Acute

Coronary

Morrow, DA, Antman, EM, Giugliano, RP, et al (2001),

Syndromes”, Circulation, 115, pp.e 356-e375.

simple risk
index for rapid initial triage of patients with ST-elevation myocardial
infarction: an InTIME II substudy", Lancet, 358 (9293), pp. 1571-1575.

Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al.

ascii om

(1996), “Improved survival with an implanted defibrillator in patients
with coronary disease at high risk for ventricular arrhythmia, Multicenter
Automatic Defibrillator Implantation Trial Investigators”, N Eng! J Med,
335, pp:1933-1940.

99. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al,

(2002), “Multicenter Automatic Defibrillator Implantation Trial II

Investigators. Prophylactic implantation of a defibrillator in patients with

myocardial infarction and reduced ejection fraction”, N Engl J Med, 346,
pp: 877-883.

100. Moss AJ. (1983
infarction”, N Engl J Med, 309 (6), pp.331-336.

101. Muller C, Buettner HJ, Hodgson JM, et al (2002), “Inflammation and

isk stratification and survival after myocardial

long-term mortality after non — ST elevation acute coronay synsdrome

treated with a very early invasive strategy in 1042 consecutive patients”,

pp.1412-1415.

102. Naber CK, Mehta RH, Júnger C, et al (2009), “Impact of Admission
Blood Glucose on Outcomes of Nondiabetic Patients With Acute ST-

Circulation, 1

Elevation Myocardial Infarction (from the German Acute Coronary
‘Syndromes [ACOS] Registry)", Am J Cardiol, 103, pp. 583-587.

103. Newby, KH, Thompson, T, Stebbins, A, et al, for the GUSTO
Investigators (1998),

stained ventricular arrhythmias in patients

Circulation,

receiving thrombolytic therapy: Incidence and outcomes’
98 (23), pp. 2567-2573.

104. Nick T., Kremlin W., Prachi B., Kate S. et al (2012), “Coronary heart
disease stati

ics. A compendium of health statistics- 2012 ed >, British
Heart Foundation Health Promotion Research Group, Department of
Public Health, University of Oxford.

ascii om

105. Niehuis MB, Ottervanger JB, Dambrink JE, et al (2009), “Comparative

predictive value of infract location, peak CK, and ejection fraction after

primary PCI for ST elevation myocardial infraction”, Coronary Artery
Dis, 20, pp9-14.
106. Nienhuis, MB, Outervanger, JP, Menko-Jan de Boer, et al (2008),

"Prognostic importance of creatine kinase and creatine kinase-MB after

primary percutaneous coronary intervention for ST-elevation myocardial
infarction”, Am Heart J, 155, pp. 673-679.

107. Núñez J, Núñez E, Bodí V, et al (2008), "Usefulness of the Neutrophil to
Lymphocyte Ratio in Predicting Long-Term Mortality in ST Segment
Elevation Myocardial Infarction", Am J Cardiol, 101,pp. 747-752. . [71]

108. O'Donoghue, de Lemos JA et al ( 2006), “Prognostic utility of Heart-type

fatty aci
Circulation, 114 (6), pp:550-557.

109. Ohman EM, Amstrong PW, Christenson RH, et al (1996),

|. GUSTO IIA

binding protein in patients with acute coronary syndromes”,

Cardiac
troponin T levels for rick stratification in acute infra
Investigators”, N Eng J Med, 335, pp.1333-1341.

110. Ohman EM, Armstrong PW, White HD, et al (1999), “Risk stratification

with a point-of-care cardiac troponin T test in acute myocardial

infarction”, Am J Cardiol, 84, pp. 1281-1286

111. Okamoto F, Sohmiya K, Ohkaru Y, Kawamura K, Asayama K, Kimura
H, Nishimura $, Ishii H, Sunahara N, Tanaka T (200), “Human heart-
type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis
of acute myocardial infarction: clinical evaluation of H- FABP in
comparison with myoglobin and creatine kinase isoenzyme MB”, Clin
Chem Lab Med, 38, pp.231-238,

112. Ottani F, Galvani M, Nicolini FA, et al (2000), “Elevated cardiac

ascii om

troponin levels predict the rick of adverse outcome in patiens with acute
coronary syndroms”, Am Heart J, 140, pp.917-927

113. Palmeri, ST, Lowe, AM, Sleeper, LA, Saucedo, JF, Desvigi
Hochman, JS (2005), "Racial and ethnic differences in the treatment and

outcome of cardiogenic shock following acute myocardial infarction”,
Am J Cardiol; 96(8),pp. 1042-1049.

114, Patel, MR, Mahaffey, KW, Armstrong, PW, et al (2005), "Prognostic
usefulness of white blood cell count and temperature in acute myocardial
infarction (from the CARDINAL Trial)", Am J Cardiol, 95 (5),pp- 614-618.

115. Peterson ED, Shaw LJ and at al (1997), “Risk Stratification after
Myocardial Infraction”, Annals of Internal Medicine, 126, pp. 556-582.

116. Pizzetti, F, Turazza, FM, Franzosi, MG, et al (2001), “Incidence and
prognostic significance of atrial fibrillation in acute myocardial

: the GISSI-3 data”, Heart, 86 (5), pp. 52

117. Richards, A. M., Nicholls, M. G., Yandle, T. G. et al. (1998), “Plas

infarct

terminal pro-brain natriuretic peptide and adrenomedullin: new
neurohormonal predictors of left ventricular function and prognosis after
myocardial infarction”, Circulation, 97, pp.1921-1929.

118. Sabatine MS, Morrow DA, Cannon CP, et al (2002), “Relationship
between baseline white blood cell count and degree of coronary artery
disease and mortality in patients with acute coronary syndromes: A
TACTICS-TIMI 18 substud

119. Sabatine, MS, Morrow, DA, Giugliano, RP, et al (2005), "Association of

‘Am Coll Cardiol, 40, pp. 1761-1768.

hemoglobin levels with clinical outcomes in acute coronary syndromes",
Circulation, 111 (16), pp. 2042-2049.
120. Savonitto, S, Granger, CB, Ardissino, D, et al (2002), "The prognostic

value of creatine kinase elevations extends across the whole spectrum of

ascii om

acute coronary syndromes", J Am Coll Cardiol, 39 (1), pp. 22-29.
121. Savotitto E.D, Ardissino D, and et al (1999), “Prognostic value of the
JAMA, 281, pp.707-713.
122. Seino Y, Ogata K, Takano T, Ishii J, Hishida H, Morita H, Takeshita H,

Takagi Y, Sugiyama H, Tanaka T, Kitaura Y (2003), “Use of a whole

adminssion ECG in acute coronary syndromes

blood rapid panel test for heart-type fatty acid-binding protein in patients
with acute chest pain: comparison with rapid troponin T and myoglobin
tests”, Am J Med, 115, pp.185-190.

123. Sharir T, Germano G, Kang X, Lewin HC, Miranda R, Cohen I,
et al. (2001), “Prediction of myocardial infarction versus cardiac
death by gated myocardial perfusion SPECT: risk stratification by the
amount of stress-induced ischemia and the poststress ejection
fraction”, J Nucl Med, 42 (6), pp:831-837.

124. Shlipak, MG, Heidenreich, PA, Noguchi, H, et al (2002), "Association of
renal insufficiency with treatment and outcomes after myocardial
infarction in elderly patients", Ann Intern Med, 137 (7), pp. 555-5

125. Sinnaeve PR, Steg PG,

Fox KA, et al (2009), "Association of Elevated
Fasting Glucose With Increased Short-term and 6-Month Mortality in
ST-Segment Elevation and Non-ST-Segment Elevation Acute Coronary
Syndromes", Arch Intern Med, 169, pp. 402-409.

126. Sobel B.E., Bresnahan G.F. Shell W.E, Yoder R.D. (1972),
“Estimation of infarct size in man and its relation to prognosi
Circulation, 46, pp:640-648.

127. Sobel B.E., Roberts R., Henry P.D.(1975
enzymatic estimation of infarct size”, Circulation, 52, pp:743-754.

128. Stavros G.D.Michael JJ et al(2009), “Long-Term Survival and

‘An improved basis for

Outcomes after Hospitalization for Acute Myocardial Infarction

ascii om

Complicated by Cardiogenic Shock”, Clin. Cardiol, 32(8), pp.E4- ES.
129. Stefan K. James et al.(2003), “N-Terminal Pro-Brain Natriuretic Peptide

and Other Risk Markers for the Separate Prediction of Mortality and
Subsequent Myocardial Infarction in Patients With Unstable Coronary
Artery Disease A Global Utilization of Strategies To Open occluded
arteries (GUSTO)-IV Substudy”, Circulation, 108, pp.275-281

130. Steg, PG, Dabbous, OH, Feldman, LJ, et al (2004), "Determinants and
prognostic impact of heart failure complicating acute coronary

syndromes: observations from the Global Registry of Acute Coronary
Events GRACE)", Circulation,109 (4), pp. 494-499.

131. Stone PH, Muller JE, Hartwell T, et al (1989), "The effect of diabetes
mellitus on prognosis and serial left ventricular function after acute
myocardial infarction: contribution of both coronary disease and left
ventricular dysfunction to the adverse prognosis. The MILIS Study
Group”, J Am Coll Cardiol, 14, pp. 49-57.

132. Talwar, S., Squire, 1. B., Downie, P. F. et al. (2000), “Profile of plasma N-

terminal proBNP following acute myocardial infarction; correlation with

left ventricular systolic dysfunction”, Eur. Heart J, 21, pp.1514-1521.

133. Thomas A. Pearson et al.(2003), “Markers of Inflammation and

Cardiovascular Dis

se Application to Clinical and Public Health

Practice: A Statement for Healthcare Professional:

pp. 499-511.

: Circulation, 107,

134. TKS Zee V.D.(2010), “C reative protein in myocardial infraction binds to
circulating micropedtid but is not associated with complement
activation”, Clinical immunology, 135, pp.490-495.

135. Toma M, Fu Y, Wagner G, et al (2008), "

isk stratification in ST-

elevation myocardial infarction is enhanced by combining baseline ST

ascii om

deviation and subsequent ST-s

136. Tu, JV, Austin, PC, Walld, R, et al (2001), "Development and validation

‚ment resolution", Heart, 94, pp. e6.

of the Ontario acute myocardial infa
Am Coll Cardiol, 37,pp. 992- 997.
137. Viswanathan K1, Kilcullen N et al (2010).

ction mortality prediction rules’

cart-type fatty acid-binding

protein predicts long-term mortality and re-infaretion in consecutive

patients with suspected acute coronary syndrome who are troponin-

J Am Coll Cardiol, 5523), pp.2590-2598.

138. Volpi A, De VC, Franzosi MG, et al (1993), "Determinants of 6-month
‘mortality in survivors of myocardial infarction after thrombolysis.

Results of the GISSI-2 data base. The Ad Hoc Working Group of the

Gruppo Italiano per lo Studio della Sopravvivenza nellinfarto
Miocardico (GISSD-2 Data Base”, Circulation, 88, pp. 416- 429.
139. Volpi, A, Cavalli, A, Santoro, L, et al, on behalf of the GISSI-2

Investigators (1998), "Incidence and prognosis of early primary
ventricular fibrillation in acute myocardial infarction-results of the
Gruppo Italiano per lo Studio della Sopravvivenza nell Infarcto
Miocardico (GISSI-2) database", Am J Cardiol, 8203), pp. 265- 271.

140. Weber M and Hamm C (2006), Role of B-type natriuretic peptide (BNP)
and NT-pro BNP in clinical routine, Heart, 92, pp. 843-849,

141. Weir RA, McMurray JJ, Velazquez EJ (2006), Epidemiology of heart
failure and left ventricular systolic dysfunction after acute myocardial
infarction: prevalence, clinical characteristics, and prognostic
importance, Am J Cardiol, 97 (10A), pp.13F-25F.

142. Whalley, GA, Gamble, GD and Doughty, RN (2006), "Restrictive

diastolic filling predicts death after acute myocardial infarction

systematic review and meta-analysis of prospective studies", Heart,

ascii om

92(11), pp. 1588- 1594.

143. Williams BA, Wright RS, Murphy JG, et al (2006), "A new simplified

immediate prognostic risk score for patients with acute myocardial
infarction", Emerg Med J, 23, pp. 186-192.

144. Witteveen SA, Hermens WT, Hollaar L, Hemker HC (1971)
“Quantitation of enzyme release from infarcted heart muscle”, Br Heart
1,331), pp:151

145. Wiviott, SD, Morrow, DA, Frederick, PD, et al (2004), "Performance of
the Thrombolysis in Myocardial Infarction risk index in the National
Registry of Myocardial Infarction-3 and -4: a simple index that predicts
‘mortality in ST-segment elevation myocardial infarction”, J Am Coll
Cardiol, 44(4), pp. 783- 789.

146. Wiviott, SD, Morrow, DA, Frederick, PD, et al (2006), " Application of
the Thrombolysis In Myocardial Infarction Risk Index in Non-ST-
Segment Elevation Myocardial Infarction: Evaluation of Patients in the
National Registry of Myocardial Infarction", J Am Coll Cardiol, 47(8),
pp: 1553- 1558.

147. Wodzig KW, Kragten JA, Hermens WT, Glatz JF, Van Dieijen-Visser

MP.(1997), “Estimation of myocardial infarct size from plasma
myoglobin or fatty acid-binding protein. Influence of renal function”, Eur
J Clin Chem Clin Biochem, 35, pp.191-198.

148. Wong, CK, White, HD, Wilcox, RG, et al (2000), "New atrial fibrillation
after acute myocardial infarction independently predicts death: the
GUSTO-I experience”, Am Heart J, 140 (6), pp. 878- 885,

149. World Health Organization (2012), “Cardiovascular Disease: Global
Atlas on Cardiovascular Disease Prevention and Control”, Geneva,

Switzerlan,

ascii om

150. Wright, RS, Reeder, GS, Herzog, CA, et al (2002),

¡cute myocardial
infarction and renal dysfunction: a high-risk combination", Ann Intern
Med, 137 (7), pp. 563- 570.

151. Wu E, Ontiz JT, Tejedor P, Lee DC, Bucciarelli-Du

(2008), “Infarct size by contrast enhanced cardiac magnetic resonance is

i C, Kansal P, et al

a stronger predictor of outcomes than left ventricular ejection fraction or
end-systolic volume index: prospective cohort study”, Heart, 94(6),
pp.730-736.

152. Wu, AH, Parsons, L, Every, NR,Bates, ER (2002), "Hospital outcomes in
patients presenting with congestive hear failure complicating acute myocardial
infarction. A report from the Second National Registry of Myocardial
Infarction (NRMI-2)", J Am Coll Cardiol, 40 (8), pp. 1389-1394.

€. TIENG PHAP

153. Assurance Maladie (2013), "Rapport de l'assurance maladie sur les

charges et produits pour l'année 2013", France,

154. Dujardin J.J., Cambou J. P.(2005), “Epidémiologie de l'infarctus du
myocarde”, Eneycl. Med. Chir, Cardiologie, pp : 11-030.

ascii om